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The imposition of ischaemia reperfusion episodes in frequently used cardiac surgery 
interventions involving cardiopulmonary bypass can induce perioperative complications, such 
as myocardial injury, arrhythmias, and end organ injury. The presence of pre-existing cardiac 
pathologies, such as hypertrophic cardiomyopathy potentiates these perioperative 
complications and results in reduced outcome benefits. A new class of carbon monoxide 
delivery molecules (oCOms) have been developed as potential anti-ischaemic agents. The 
present study investigated the cardioprotective potential of oCOm-21 in normotrophic, 
moderately and severely hypertrophic hearts subjected to an acute ischaemia reperfusion 
episode. 
 
Hypertension induced in 8 week old male Cyp1a1-Ren2 rats fed indole-3-carbinol (0.167 % 
w/w; 8 – 12 weeks) resulted in elevated systolic blood pressures (79.7 % increase), larger heart 
weights (61 % greater) and increased left ventricular fibrosis (75 % increase) against control 
littermates. Hearts were isolated and perfused using the Langendorff technique. oCOm-21 (1 – 
10 µM), the non-CO releasing derivative of oCOm-21 (DB-21) or vehicle control was infused 
(10 minutes) prior to a 30 minute warm global ischaemic episode followed by a 60 minute 
reperfusion period. In normotrophic hearts (n = 3 - 5/group), oCOm-21 (1 and 3 µM) improved 
left ventricular haemodynamic recovery of left ventricular developed pressure, coronary flow 
rate, heart rate and dP/dtmax and dP/dtmin to pre-ischaemic baseline values. In hypertrophic 
hearts (n = 7 - 11/group), left ventricular haemodynamic recovery to respective pre-ischaemic 
baselines was improved when higher concentrations (3 and 10 µM) of oCOm-21 were applied, 
with moderately hypertrophic heats showing greater recovery than severely hypertrophic 
hearts. Furthermore, oCOm-21 (3 and 10 µM) decreased myocardial injury as seen by the 
reduction of lactate dehydrogenase leakage upon reperfusion in the normotrophic and 
hypertrophic hearts compared to respective baseline values, and a reduction in apoptotic cell 
death at 60 minutes of reperfusion with oCOm-21 (1 and 3 µM; P < 0.01). 
 
This study provides valuable evidence supporting oCOm-21 use as a pre-ischaemic agent for 
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1.1 Introduction Overview 
Cardiovascular diseases (CVDs) are the number one cause of death worldwide accounting for 
over 18 million deaths each year, as reported by the World Health Organisation (Forouzanfar 
et al., 2016; Wang et al., 2016). It has been reported that approximately 1 – 1.25 million 
cardiac surgical interventions utilising cardiopulmonary bypass (CPB) are conducted globally 
each year (Herbertson, 2004; McGuinness et al., 2016). Ischaemia reperfusion (I/R) injury 
occurring from cardiac surgical interventions utilising CPB is associated with perioperative 
complications which adversely affect postoperative outcomes in patients (Walsh et al., 2008; 
Shroyer et al., 2017; Kamenshchikov et al., 2019). Patients with underlying cardiac 
pathologies are at an increased risk for the development of these perioperative complications 
(Scrutinio and Giannuzzi, 2008; Toumpoulis et al., 2009; Wang et al., 2016). Therefore, 
cardioprotective strategies need to be developed above what is currently in use during cardiac 
surgical procedures.  
 
1.2 Myocardial Ischaemia Reperfusion Injury 
Jennings et al. first described the phenomenon of I/R injury when observing that reperfusion 
of the canine heart following coronary ligation, resulted in the accelerated development of 
myocardial necrosis; greater than if the coronary artery was ligated and not reperfused for 24 
hours (Jennings et al., 1960). I/R induced myocardial dysfunction can present as myocardial 
“stunning”, arrhythmias, microvascular obstruction, myocardial infarction and an 
inflammatory response, all of which affect end-organ perfusion (Zweier et al., 1987; Butler et 
al., 1993; Itoh et al., 2004; Solaini and Harris, 2005; Hausenloy and Yellon, 2016).  
 
1.2.1 Mechanism of Injury  
1.2.1.1 Ischaemic injury  
Following the onset of ischaemia, myocardial cell death begins at 20 minutes under 
normothermic conditions, however, if revascularisation of the tissue occurs between 20 - 30 
minutes, the ischaemic damage sustained by the myocardium is largely reversible (Jennings 
and Reimer, 1991; Michiels, 2004). Ischaemia results in altered ion homeostasis and 
metabolism which in turn alters structural organisation, produces mitochondrial swelling and 
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intracellular oedema, reduced cardiac contractility, inducing cell death by necrosis and 




Figure 1.1 Schematic diagram representing the key cellular alterations during ischaemia in a 
cardiomyocyte. Reduced oxygen leads to a shift from aerobic to anaerobic respiration, causing reduced 
cellular ATP, reduced activity of ATP dependent ion channels and decreased intracellular pH. Decreased 
intracellular pH inhibits opening of the mitochondrial permeability transition pore (mPTP), inhibits 
contraction of myofibrils and leads to increased sodium hydrogen exchanger (NHX) activity. The sodium 
calcium exchanger (NCX) works in reverse to excrete intracellular sodium (Na+) leading to an increased 
intracellular calcium (Ca2+) (Adapted from Zaugg et al., 2004). 
 
As described in Figure 1.1, the ischaemic episode rapidly depletes the O2 in the myocardial 
tissue with aerobic respiration suspended and anaerobic glycolysis initiated (Jennings, 1969; 
Levitsky and Feinberg, 1975; Smith et al., 1993). Anaerobic glycolysis, however, cannot 
generate sufficient ATP required to prevent dysfunction of ATP-dependent ion exchangers 
and subsequent tissue acidosis (Marban et al., 1987; Stanley et al., 1992; Kim et al., 2013). 
Tissue acidosis increases intracellular Na+ resulting in intracellular oedema, which contributes 
to necrotic cell death by rupturing the plasma membrane (Pike et al., 1993; Smith et al., 1993; 
Murphy and Steenbergen, 2008; Kalogeris et al., 2012). The increased activity of the 
Na+/Ca2+ exchanger and the opening of “long lasting” (L-type) voltage gated Ca2+ channels, 
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cause cytosolic Ca2+ overload, further facilitating ischaemic injury through mitochondrial 
swelling and activation of degradation enzymes, such as lipases and proteases (Weber et al., 
2003; Imahashi et al., 2004; Singh et al., 2004). These degradation enzymes can consequently 
activate pro-apoptotic proteins and damage plasma membrane integrity leading to cell death 
(Weber et al., 2003; Kalogeris et al., 2012; Gorlach et al., 2015).  
 
1.2.1.2 Reperfusion injury 
Following a sustained period of ischaemia, reperfusion triggers Ca2+ overload, oxidative 
damage and inflammation (Zweier et al., 1987; Wei et al., 2007; Kalogeris et al., 2012). Ca2+ 
overload upon reperfusion, shown in Figure 1.2, can result in myofibril hypercontracture, 
ultrastructural mitochondrial damage, ATP depletion and myocardial stunning (Zimmerman, 
1967; Kusuoka et al., 1987; Di Lisa et al., 2001; Ruiz-Meana et al., 2007). Further, increased 
intracellular Ca2+ can initiate arrhythmias, which are significant contributors to myocardial 
dysfunction and mortality in I/R injury (Opie and Coetzee, 1988; Tani et al., 1996). Ca2+ 
overload in combination with the rapid normalisation of pH and oxidative stress upon 
reperfusion results in the opening of the mitochondrial permeability transition pore (mPTP) 
(Lindsay et al., 2015; Seidlmayer et al., 2015). Opening of the mPTP impairs the 
mitochondrial electrochemical gradient, thereby, impairing ATP production and promoting 
the release of reactive oxygens species (ROS) and pro-apoptotic-inducing proteins such as 
cytochrome C from the mitochondria to initiate cell death (Kim et al., 2006; Zhu et al., 2018). 
In myocardial I/R injury, two major forms of cell death indicated are apoptosis (ATP-
dependent) and necrosis (ATP-independent) (Dumont et al., 2000; Zhao et al., 2000b; Kim et 
al., 2006). Ultimately, ionic cellular changes and ROS result in functional injury as seen by an 
impaired contractile function of the myocardium, and have been reported as a primary cause 
of myocardial stunning observed at reperfusion (Bolli et al., 1989; Wei et al., 2007; Kals et 
al., 2008). Another established factor contributing to reperfusion injury is inflammation both 
at a local and systemic level (Kloner et al., 1991; Gwechenberger et al., 1999; Kawaguchi et 




Figure 1.2 Schematic diagram representing the key cellular alterations during reperfusion in a 
cardiomyocyte. Restoration of oxygen restores aerobic respiration, triggers ROS and increases intracellular 
ATP restoring function of ATP dependent channels. Activation of sarcoplasmic reticulum SERCA clears 
cytosolic calcium (Ca2+) accumulation from ischaemia with rapid repetitive opening of ryanodine receptor 
(RYR) causing myofibril hypercontracture. Increased intracellular Ca2+ and mitochondrial oxidative stress 
and rapid restoration of physiological pH result in the opening of the mitochondrial permeability transition 
pore (mPTP). mPTP opening triggers cell death via impaired mitochondrial electrochemical gradient, 
impaired ATP production and release of ROS and cytochrome C from the mitochondria (Adapted from 
Zaugg et al., 2004). 
 
1.2.2 Ischaemia Reperfusion Injury in Cardiac Surgical Interventions  
Acute coronary revascularisation interventions, such as coronary artery bypass graft (CABG) 
surgeries and valvular corrective surgeries, performed using “on pump” cardiopulmonary 
bypass (CBP) or “off pump” protocols, comprise the most common major surgical procedures 
worldwide (Goldman et al., 2004; Lloyd-Jones et al., 2010; Weisse, 2011). An estimated 
800,000 CABG surgeries are conducted globally each year and are the most common cardiac 
surgical procedure required for the improvement of symptoms and prevention of myocardial 
infarction (MI) and subsequent death arising from coronary artery disease (Goldman et al., 
2004; Lloyd-Jones et al., 2010; Weisse, 2011; Gerczuk and Kloner, 2012).  
 
Protecting the heart from I/R injury during cardiac surgery is of high importance to reduce the 
incidence and severity of complications such as arrhythmias, low-output cardiac failure, MI, 
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stroke, and systemic inflammation; in order to improve clinical outcomes morbidity, 
mortality, intensive care unit (ICU) length of stay and total hospital length of stay (Chen et 
al., 2007; Shen et al., 2011). It is important to note that I/R injury resulting from cardiac 
surgery is distinctly different from I/R injury arising from acute spontaneous MI. Ischaemia 
during cardiac surgery is a controlled process, managed by preservation strategies (discussed 
below) and monitoring. The controlled surgical environment provides an opportunity to pre-
emptively provide pharmacological conditioning agents, such as the carbon monoxide (CO) 
donors, to protect against I/R injury and improve left ventricular function and surgical 
outcomes.  
 
1.2.2.1 Cardiopulmonary bypass 
CPB is a technique utilised in cardiac surgical interventions to correct cardiopulmonary 
diseases, such as coronary artery disease, congenital cardiac and valvular defects, and organ 
replacement surgeries such as cardiac cardiopulmonary transplantation. CPB technology 
provides a motionless and clear surgical field for surgeons performing cardiac interventions 
(Machin and Allsager, 2006). The extracorporeal circuit is a feature of CPB which 
temporarily takes over the function of the heart and lungs to manually circulate oxygenated 
blood to the organs and tissues while isolating the heart from the systemic circulation (Machin 
and Allsager, 2006). This procedure however, produces an acute global ischaemic episode, 
which if prolonged can result in myocardial dysfunction upon reperfusion arising from 
pathological changes associated with ischaemia reperfusion (I/R) injury and systemic 
inflammation (Kuratani et al., 1992; Butler et al., 1993; Freyholdt et al., 2003; Chello et al., 
2006; Bronicki and Hall, 2016). These pathological changes impact on postoperative 
morbidity and mortality (Kuratani et al., 1992; Butler et al., 1993; Afilalo et al., 2012). 
Several interventions have been utilised to reduce the injury arising during the ischaemic 
episode, which will be discussed further on in this thesis.  
 
While it had been suggested that in acute coronary procedures, CABG, the use of “off pump” 
protocols rather than CPB would improve surgical morbidity and mortality rates this has been 
disproved (Shroyer et al., 2009; Afilalo et al., 2012; Shroyer et al., 2017; Cuminetti et al., 
2019). “Off pump” CABG involves operating on a restrained area of a beating heart with an 
uninterrupted flow of blood to the non-surgical region of the heart. A meta-analysis 
comparing postoperative outcomes of 8961 patients in 59 trials who underwent CABG using 
CPB and those who underwent CABG “off pump” found little to support this concept (Afilalo 
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et al., 2012). Analysis of the adverse outcomes measured (mortality, stroke and MI) showed 
no difference between surgical procedures conducted using CPB or “off pump” protocols 
(Afilalo et al., 2012; Shroyer et al., 2017; Cuminetti et al., 2019). 
 
1.2.2.2 Preservation techniques in cardiac surgical interventions  
Cardioplegia remains the current gold standard for protecting the heart during cardiac surgery 
(Chambers and Fallouh, 2010). While the exact components of crystalloid based and blood 
based cardioplegic solutions vary, the solutions all contain moderate to high potassium 
concentrations (Habertheuer et al., 2014). The cardioplegic cannula is inserted anterograde 
into the aortic root and/or retrograde into the coronary sinus. The cannula allows for the 
delivery of the cardioplegic solution which will cause temporary, reversible electrochemical 
cardiac arrest (in diastole) to reduce the myocardial oxygen consumption and prevent cardiac 
damage, allowing for reduced intraoperative myocardial injury and reduced postoperative 
complications (Goto et al., 1991; Chambers and Fallouh, 2010). While cardioplegia does 
provide a degree of cardiac protection, the heart still suffers an ischaemic episode and is still 
vulnerable to damage and complications associated with I/R injury (Afilalo et al., 2012; 
Hoyer et al., 2017; Cuminetti et al., 2019). This continued vulnerability to I/R injury has led 
to the search for an effective cardioprotective strategy. 
 
1.3 Ischaemic Conditioning  
1.3.1 Pre-ischaemic conditioning  
Classic cardiac ischaemic preconditioning (IPC) is a technique in which the heart undergoes 
repeated periods of brief mechanical vascular occlusions producing non-lethal IR to protect 
the heart against a subsequent prolonged period of ischaemia. This technique was first 
discovered by Murry et al. in 1986 when they found that subjecting the canine heart to four 5 
minute periods of ischaemia and reperfusion through occluding the left anterior descending 
coronary artery resulted in a 75% reduction of MI size when measured at 72 hours following 
40 minutes of sustained ischaemia (Murry et al., 1986). Since the discovery by Murry et al. 
(1986) preconditioning protection has been established in all species and organs tested 
including in the human heart (Li et al., 1990; Schott et al., 1990; Cohen et al., 1991; Yellon et 
al., 1993; Yellon and Downey, 2003). Following IPC there are two windows of protection, 
the initial lasting 2 – 3 hours and the second which occurs at 12 – 24 hours and lasts until 72 




1.3.1.1 Signalling pathways underlying IPC 
Myocardial protection afforded by IPC is mediated by increased intracellular Ca2+, increased 
intracellular nitric oxide (NO) and mitochondrial derived ROS, resulting in the activation and 
translocation of protein kinase C epsilon (PKCε) (Dekker et al., 1996; Baines et al., 1997; 
Xuan et al., 2000; Baines et al., 2002). IPC generates the classical endogenous autacoids, 
adenosine, bradykinin and opioids, which bind to their respective G-protein coupled receptors 
(GPCRs) activating a number of intracellular signals through the phosphoinositide 3-kinase 
(PI3K) pathway (Liu et al., 1991; Parratt, 1994; Tsuchida et al., 1994; Goto et al., 1995; Liu 
et al., 1995; Schultz et al., 1995; Wang et al., 1996; Toyoda et al., 2000). IPC activates 
endothelial nitric oxide synthase (eNOS) as an immediate but short-term response to produce 
NO and activates inducible nitric oxide synthase (iNOS) during the second window of 
protection (Xuan et al., 2000; Zhao et al., 2000a; Yang et al., 2012). NO is an important 
mediator of the IPC signalling pathway through soluble guanylyl cyclase (sGC) pathway 
activation inducing the formation of oxidative species, activating PKCε and mediating the 
opening of mitochondrial KATP channels through the cGMP/PKG pathway (Costa and Garlid, 
2008; Abete et al., 2011; Sun et al., 2013). Mitochondrial KATP channel are key regulators of 
the mitochondrial volume, mitochondrial membrane potential and the formation of ROS and 
ATP (Garlid, 1980; Sackin and Palmer, 1987; Yellon et al., 1993; Iwai et al., 2000; Debska et 
al., 2001; Debska et al., 2002). Mitochondrial ROS released following an IPC stimulus 
further result in the activation of the pro-survival protein kinases; PKC, extracellular signal-
regulated kinase 1 and 2 (Erk1/2) and mitogen-activated protein kinase (p38 MAPK) to 
reduce cell death and inflammation (Baines et al., 1997; Yue et al., 2001; Samavati et al., 
2002).  
 
1.3.2 Post-ischaemic conditioning  
Cardiac ischaemic postconditioning (IPostC) in contrast is a technique in which the heart 
undergoes periods of intermittent reperfusion following a prolonged episode of ischaemia to 
protect against I/R injury. Zhao et al. (2003) first presented evidence for a cardioprotective 
effect through the gradual restoration of blood flow with 3 cycles of 30 seconds reperfusion 
and 30 seconds ischaemia immediately following a prolonged coronary artery occlusion in a 
dog (Zhao et al., 2003). It was found that this IPostC protocol reduced infarct size, reduced 
plasma necrosis markers and improved haemodynamic recovery (Zhao et al., 2003). This 
finding of cardioprotection has since been replicated in a number of studies using different 
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species and different IPostC protocols (Tsang et al., 2004; Yang et al., 2005; Iliodromitis et 
al., 2006; Penna et al., 2006; Philipp et al., 2006; Sivaraman et al., 2007). 
 
1.3.1.2 Signalling pathways underlying IPostC 
A large number of the signalling pathways involved in the myocardial protection, afforded by 
IPostC, are shared with IPC. The endogenous autacoid GPCRs are activated (adenosine, 
bradykinin and opioid receptors), leading to the activation of the PI3K pathway (Tsang et al., 
2004; Yang et al., 2004; Yang et al., 2005). PI3K activates protein kinase B (AKT) and 
eNOS, producing NO as an immediate but short-term response and activating sGC which 
subsequently activates PKC and cGMP/PKG signalling which mediates the opening of the 
mitochondrial KATP channel and consequently inhibit the opening of the mPTP and cellular 
death (Tsang et al., 2004; Yang et al., 2004; Philipp et al., 2006; Sivaraman et al., 2007; 
Krieg et al., 2009). The cGMP/PKG signalling has also been shown to protect against the 
opening of the mPTP channel, and subsequent cell death, by delaying the normalisation of pH 
upon reperfusion through inhibiting the NHE (Sun et al., 2006; Zhao et al., 2007). 
 
1.4 Pharmacological Cardioprotective Conditioning Agents 
Understanding the triggers and mediators of IPC and IPostC has allowed for the development 
of novel pharmacological interventions that trigger the biochemical signalling cascade of 
ischaemic conditioning without inducing ischaemia. Pharmacological preconditioning 
presents a safer manner of providing cardioprotection, as the IPC protocol has been associated 
with issues surrounding the invasive requirement of direct application of the conditioning 
stimulus to the heart and further, the risk of arterial thromboembolism formation from cross 
clamping and unclamping of the aorta (Zaugg et al., 2003; Hausenloy et al., 2012).  
 
There have been several pharmacological conditioning agents which have been investigated. 
These include the exogenous administration of endogenous gasotransmitters such as NO, 
carbon monoxide (CO) and hydrogen sulphide (H2S), KATP channel openers, volatile 
anaesthetics, cyclosporine A, exogenous administration of endogenous compounds such as 
adenosine, bradykinin and opioids; all of which have been shown to reduce cardiac damage 
following I/R in a research setting (Lefer et al., 1993; Schultz et al., 1997; Julier et al., 2003; 
Liu et al., 2007; Skyschally et al., 2010; Soeding et al., 2011; Zhao et al., 2013; Kueh et al., 
2017; Singh et al., 2017; Kiss et al., 2018). The signalling underlying NO, KATP channel 
openers and the classical autacoids have been discussed above. H2S signals through mediating 
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the opening of the KATP channels, volatile anaesthetics signal through the PI3K pathway while 
cyclosporine A confers cardioprotection through inhibiting cyclophilin D mediated mPTP 
opening (Zaugg et al., 2003; Geng et al., 2004; Argaud et al., 2005). To date, only KATP 
channel openers and volatile anaesthetics: isoflurane, sevoflurane and xenon have been 
successfully translated into a clinical setting (Julier et al., 2003; Luo et al., 2008; Kim et al., 
2012). The cardioprotective benefits of NO (40 ppm) as an adjuvant in cardioplegia has 
recently been investigated in a pilot study in human patients undergoing CABG surgery with 
CPB and will now be trialled in a larger study (Kamenshchikov et al., 2019).  
 
1.5 Carbon Monoxide 
1.5.1 Endogenous production 
CO is endogenously produced by the enzyme heme oxygenase (HO), an NADPH dependent 
enzyme responsible for the catabolism of heme into free iron (Fe2+), CO and biliverdin 
(Tenhunen et al., 1968). Currently, there are three identified isoforms of HO; HO-1, HO-2 
and HO-3 (Maines, 1997; Motterlini et al., 2002). The enzymatic isoform HO-1 is inducible 
by the stress response gene HMOX1 and is primarily expressed in the endoplasmic reticulum, 
whereas HO-2 and HO-3 are constitutively active in all examined tissues throughout the body 
(Maines et al., 1986; Mccoubrey et al., 1997). Endogenous CO in mammalian cells is 
produced at low concentrations ranging from 10 to 500 ppm and is an essential signalling 
molecule in the cardiovascular system, central nervous system and the immune system 
(Sammut et al., 1998; Foresti and Motterlini, 1999; Motterlini et al., 2002b).  
 
1.5.2 CO as a pharmacological preconditioning agent 
Experimental evidence to date supports exogenously applied CO as a beneficial 
preconditioning agent for myocardial I/R injury, provided that the haemoglobin oxygen 
carrying capacity is not severely compromised (HbCO < 20%) (Guo et al., 2004; Lavitrano et 
al., 2004; Foresti et al., 2008; Adams et al., 2017). The endogenous production, the ability to 
reversibly bind to molecular targets and the reduced reactivity (lower than NO and H2S), 
presents major advantages of CO as a therapeutic agent (Queiroga et al., 2012). The 
cardioprotective properties of CO attenuate I/R injury through modulating inflammation, 
reducing cell death, vasodilation, inhibiting platelet aggregation and protecting endothelial 
cells (Furchgott and Jothianandan, 1991; Otterbein et al., 2000; Chlopicki et al., 2006; 
Zuckerbraun et al., 2006; Wang et al., 2007; Foresti et al., 2008). The protective properties of 
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CO are mediated through a large number of signalling pathways, such as the sGC pathway, 
the NO independent pathway, p38 MAPK, AKT, mitochondrial ROS, PKCε and inhibition of 
heme degradation (These pathways are summarised in Figure 1.3) (Otterbein et al., 2000; 
Nakao et al., 2014).  
 
 
Figure 1.3 Signalling of carbon monoxide as a pharmacological preconditioning agent. CO has 
vasodilatory, cytoprotective and anti-inflammatory properties. At the mitochondrial level CO inhibits 
complex 4 of the ETC to trigger a small burst of ROS which activates PKCε and results in the translocation 
of PKCε to the mitochondria where it improves energetics, opens the mitochondrial KATP channels and 
inhibits the opening of the mPTP.  
 
1.5.3 Carbon monoxide releasing molecules  
Motterlini and colleagues developed the first carbon monoxide releasing molecules 
(CORMs), these originally focused on transition-metal carbonyl complexes for CO delivery, 
requiring a central metal atom such as ruthenium or manganese (Motterlini et al., 2002a; 
Clark et al., 2003). These compounds allowed for low controlled doses of CO to be released 
under physiological conditions (Motterlini et al., 2002a; Motterlini et al., 2005). Cytotoxicity 
arising from the transitional metal centres have however limited the therapeutic translation of 
the CORM compounds so far (Winburn et al., 2012). Further issues arose with the first 
generation of CORMs, CORM-1 and CORM-2, due to insolubility in water (Motterlini et al., 
2002a). The chemical structures of CORMs can be manipulated, however, to allow for 
 
 11 
specific CO-release rates and increased water solubility, as seen in the development of 
CORM-3 and CORM-A1 (Motterlini et al., 2002a; Clark et al., 2003; Motterlini et al., 2005). 
Release of CO from CORMs can be achieved by external or internal triggers (Clark et al., 
2003; Rimmer et al., 2010; Romanski et al., 2012; Garcia-Gallego and Bernardes, 2014; Ji et 
al., 2017; Soboleva et al., 2017). The external triggers have largely relied on thermal 
activation and light activation (photo-CORMs) (Rimmer et al., 2012). Whereas the newer 
generation of CORMs release CO by internal triggers in physiological environments by 
exploiting physiological enzymatic reactions such as esterase and protease hydrolysis, 
exploiting redox environments and further, pH (Stamellou et al., 2014; Ji et al., 2016; Aucott 
et al., 2017; Ji et al., 2017; Kueh et al., 2017). These triggers allow for the controlled and 
specific delivery of CO to biological tissues of interest (Garcia-Gallego and Bernardes, 2014).  
 
The study by Winburn et al. highlighted the importance of developing a delivery device with 
a safe toxicological profile, good water solubility, and the ability to release CO in a controlled 
manner under physiological conditions (Clark et al., 2003; Motterlini et al., 2005; Tayem et 
al., 2006; Song et al., 2011; Winburn et al., 2012). Therefore, there has been a shift towards 
the development of organic CO releasing molecules without metal centres. The CardioRenal 
Protection group from the University of Otago Department of Pharmacology in collaboration 
with the University of Otago Chemistry Department (Larsen Group) have developed and 
synthesised organic CO releasing molecules (Kueh et al., 2017). These compounds release 
CO in a controlled manner in response to physiological pH (7.4) (Kueh et al., 2017). The 
synthesis of these compounds is based upon a norbornene substructure, which is commonly 
prepared using Diels-Alder reactions.  
 
1.5.4 oCOm-21 
The organic CO releasing molecule, oCOm-21, has been shown to release CO under 
physiological conditions (pH 7.4, 37°C) with a half-life of 19 minutes, making it a desirable 
pharmacological preconditioning agent in the clinical setting of cardiac surgery (Kueh et al., 
2017). A suitable half-life of CO release allows for efficient targeting and further, for 
adequate concentrations of CO to reach the intended tissue (Garcia-Gallego and Bernardes, 
2014). oCOm-21 is a water soluble compound with a solubility of 10.8 mg/mL at 20°C and 





The research conducted by our group to date has investigated and provided evidence for the 
use of oCOm-21 as a myocardial preconditioning agent in healthy normotrophic hearts. 
Preliminary work conducted by the CardioRenal Protection group established administration 
of oCOm-21 as a preconditioning agent in isolated normotrophic rat hearts resulted in 
protection of the myocardium when subjected to 30 minutes of ischaemia and 60 minutes of 
reperfusion as seen by the return of left ventricular developed pressure and coronary flow to 
pre-ischemic values (Adams et al., 2017). Healthy non-diseased hearts, however, do not 
represent the population of patients undergoing cardiac surgery (Lee et al., 2006; Scrutinio 
and Giannuzzi, 2008). Therefore, to determine the clinical benefit of oCOm-21 as a 
conditioning agent in cardiac surgical interventions, research needs to be conducted 
investigating oCOm-21 administration in hearts suffering from cardiomyopathies.  
 
1.6 Hypertensive Heart Disease 
1.6.1 Hypertension  
High blood pressure described clinically as hypertension (HTN), is the most prevalent and 
preventable risk factor for cardiovascular disease (CVD) (Forouzanfar et al., 2016). HTN is a 
condition in which the pressure on arterial vessels is persistently raised and is defined as a 
sustained systolic blood pressure ≥ 140 mmHg and/or a diastolic blood pressure ≥ 90 mmHg 
(Williams et al., 2018). At present, the World Health Organisation has estimated 1.13 billion 
people worldwide suffer from HTN; with the prevalence of HTN expected to increase to 1.56 
billion by 2025 (Kearney et al., 2005; Wang et al., 2016).  
For 95% of patients with HTN, the underlying mechanism for developing HTN remains 
evasive. This is due to an inability to identify a singular factor in the development of HTN 
(Forouzanfar et al., 2016). Research has however confirmed that there are non-modifiable 
factor such as genetics and aging and a large number of modifiable risk factors associated 
with HTN such as obesity, an unhealthy (high salt/sugar/fat) diet, lack of physical exercise, 
smoking, alcohol, high levels of stress, diabetes and hyperlipidaemia (Rapsomaniki et al., 
2014; Forouzanfar et al., 2016). These risk factors lead to over activity of the sympathetic 
autonomic nervous system, activation of the renin angiotensin aldosterone system (RAAS), an 
increase in inflammation mediators, oxidative stress and endothelial dysfunction (Dorffel et 




Hypertensive heart disease (HHD) arising from chronic uncontrolled HTN is a major global 
health and economic burden which has major consequences to health systems, particularly in 
small countries such as New Zealand (Kearney et al., 2005). HTN is often referred to as the 
“silent killer” as the absence of symptoms means that the detection and subsequent diagnosis 
may be missed by both patients and physicians unless deliberately assessed (Abubakar et al., 
2015; Baker et al., 2018). In New Zealand, HTN accounted for 8% of illness, disability and 
premature mortality in 2013 (Ministry of Health, 2016). Chronic elevated HTN can result in 
multiple complications including peripheral artery disease, coronary artery disease, 
congestive heart failure, MI, stroke, atrial fibrillation, aortic valve stenosis or regurgitation, 
and chronic kidney disease (Mozaffarian et al., 2015; Wang et al., 2016; Rahimi et al., 2018).  
1.6.1.2 Hypertension and myocardial left ventricular hypertrophy 
Left ventricular myocardial hypertrophy (LVH) secondary to hypertension is one of the 
indicators of organ damage and is a strong independent predictor of cardiovascular mortality 
and morbidity (Cohn et al., 2004; Meijs et al., 2010). LVH is an adaptive response in which 
the cardiac muscle mass increases, decreasing the chamber volume of the left ventricle. 
Hypertrophy of the left ventricle results in reduced capillary density due to the increased size 
of the cardiomyocytes and decreased extracellular matrix, which impairs the diffusion of O2 
and nutrients to cardiomyocytes (Zhu et al., 1996; Van Kerckhoven et al., 2004; Galati et al., 
2016). Narrowing of microvasculature lumen has also been observed in LVH due to 
microvascular remodelling and replacement fibrosis, contributing further to reduced tissue 
perfusion (Galati et al., 2016). Interstitial fibrosis present in LVH results in zones of altered 
electrical conductance, which impairs contractility, contributing to left ventricular stiffness, 
and increases the likelihood of arrhythmias (Nguyen et al., 2014; González et al., 2018). The 
reduced availability of O2 and nutrients leads to inefficient cardiac metabolism and altered 
energetics (Beer et al., 2002). The progression of LVH sees a decline in mitochondrial 
oxidative phosphorylation and a decline in mitochondrial biogenesis (Doenst et al., 2010; 
Riehle et al., 2011). LVH as the result of pressure overload associated with HTN is a well-
recognised risk factor for development of diastolic dysfunction, coronary artery disease, 
sudden death, MI, arrhythmias and congestive heart failure (Kannel et al., 1970; Hennersdorf 
and Strauer, 2001; Vakili et al., 2001). The risk of such cardiovascular events elevates with 




1.7 Cardiac Surgery and Pre-existing Underlying Cardiac Pathologies  
Consented cardiac surgical patients undergo a scoring system which takes into account 
several factors including age, sex, preoperative state and number and severity of 
comorbidities (Ferguson et al., 2002). Comorbidities are now common among patients 
undergoing acute cardiovascular interventions, such as CABG, with an increase in both the 
number and severity of comorbidities (Scrutinio and Giannuzzi, 2008; Raza et al., 2015). 
Ferguson et al., (2002) examined over one million records from patients who had undergone 
isolated CABG procedures during 1990 - 1999 from the Society of Thoracic Surgeons 
National Adult Cardiac Database. Patients undergoing CABG surgeries were more likely to 
be older and have a history of smoking, diabetes mellitus, renal failure, hypertension, stroke, 
lung disease, heart failure and three vessel blockage (Ferguson et al., 2002). The increased 
presence of comorbidities coincided with a 30% increase in the predicted risk of mortality 
following surgery (Ferguson et al., 2002). Consequently, surgical patients with multiple and 
increasingly complex comorbidities are associated with a 5 – 6% mortality rate (Hausenloy et 
al., 2012). LVH is one such comorbidity with the postoperative outcomes in patients 
associated with the severity of LVH prior to ischaemia; with severely hypertrophied hearts 
being more susceptible to reperfusion injury compared to moderately hypertrophied hearts 
(Beyersdorf et al., 1980; Itoh et al., 2004; Meijs et al., 2010). This surgical population, with 
severe hypertrophied hearts, provide greater challenges as the cardioprotective effects 
afforded by conditioning therapies and agents may be deteriorated (Ghosh et al., 2001; Itoh et 
al., 2004; Ma et al., 2018). 
 
1.8 Study Design 
1.8.1 Animal model  
Transgenic Cyp1a1-Ren2 rats were used in the study to generate hearts with left ventricular 
hypertrophy. In the Cyp1a1-Ren2 rat, mouse renin 2 (Ren2) cDNA is integrated into a 
fragment of the cytochrome P450 1a1 (Cyp1a1) promotor on the Y chromosome 
(Kantachuvesiri et al., 2001). Induction of the Cyp1a1 enzyme by oral administration of the 
aryl hydrocarbon, indole-3-carbinol (I3C) results in expression of Ren2 in the liver 
(Kantachuvesiri et al., 2001). Increased circulating renin activates the RAAS pathway leading 
to raised blood pressure as a result of Na+ reabsorption and vasoconstriction (Ruilope and 
Schmieder, 2008; Howard et al., 2011; Heijnen et al., 2014; Touyz, 2014). Induction and 
maintenance of HTN results in pressure overload in the heart (Ruilope and Schmieder, 2008; 
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Heijnen et al., 2014; Williams et al., 2018). The consequence of sustained pressure overload 
is increased cardiomyocyte size and cardiac remodelling leading to the development of LVH 
(Schillaci et al., 2000; Kavazis, 2015; Williams et al., 2018; Leader et al., 2019).  
 
1.7 Aims and Hypothesis 
1.7.1 Hypothesis  
Based on the above preliminary evidence, this study hypothesises that oCOm-21 infusion 
prior to the induction of an ischaemic event can acutely protect normotrophic as well as 
hypertrophic hearts, resulting in improved LV functional and structural recovery during 
reperfusion. It is further postulated that as hypertrophic hearts have an increased susceptibility 
to I/R injury, this pre-existing pathology may reduce the level of protection afforded by 
oCOm-21. Consequently, we proposed that the additional infusion of oCOm-21 upon 
reperfusion may further improve these indices over and above pre-ischaemic infusion alone.  
 
1.7.2 Aims 
1. To develop a clinically-relevant model of HHD in the hypertensive Cyp1a1-Ren2 rat. 
a) Establish malignant hypertension over an 8 – 12 week dosing period of 0.167 
% w/w I3C in the Cyp1a1-Ren2 rat. 
b) Confirm the development of an increased HW in the hypertensive Cyp1a1-
Ren2 rat. 
c) Confirm an increase in the degree of LV cardiac fibrosis in the hypertensive 
Cyp1a1-Ren2 rat. 
 
2. Assess the prophylactic benefit of pre-ischaemic treatment with oCOm-21 in a 
normotrophic isolated Cyp1a1-Ren2 rat heart in an ex-vivo model of I/R injury. 
a) Determine left ventricular haemodynamic parameters.  
b) Quantify myocardial cell death by necrosis. 
c) Quantify myocardial cell death by apoptosis.   
 
3. Assess the prophylactic benefit of pre-ischaemic treatment with oCOm-21 in a 
hypertrophic isolated Cyp1a1-Ren2 rat heart in an ex-vivo model of I/R injury.  
a) Determine left ventricular haemodynamic parameters.  
b) Quantify myocardial cell death by necrosis.   




4. Assess the prophylactic benefit of pre-ischaemic and post-ischaemic treatment with 
oCOm-21 in a normotrophic isolated Cyp1a1-Ren2 rat heart in an ex-vivo model of 
I/R injury. 
a) Determine left ventricular haemodynamic parameters.  
5. Investigate the significance of sGC activity in the inotropic response from oCOm-21 
derived CO. 
a) Determine the optimal concentration of the highly selective irreversible heme-
site inhibitor of sGC (ODQ) in order to inhibit coronary vascular sGC activity 





























2.1 Materials and Reagents  
All reagents were purchased from BDH (Palmerston North, New Zealand) and Sigma-Aldrich 
(Auckland, New Zealand) unless otherwise specified. Animal prescription drugs were 
obtained from the University of Otago Animal Welfare Office.  
2.2 Animals 
Male Cyp1a1-Ren2 transgenic rats (n = 76) were obtained from the Animal Resource Unit 
(University of Otago, Dunedin, New Zealand) at 6 weeks old. Animals were housed in a 
temperature (21 ºC) and humidity controlled (40 – 60 %) room with a 12-hour light/dark 
cycle. Rats had access to rat chow and water ad libitum. All animal procedures were approved 
by the University of Otago’s Animal Ethics Committee.  
2.2.1 Experimental protocol  
On arrival at the animal holding unit, the experimental animals underwent a familiarisation 
period (2 weeks) of animal handling and restraining in order to allow them to become 
familiarised to the blood pressure monitoring procedure. At 8 weeks of age, animals were 
randomly assigned to either the normotensive group and kept on the standard rat chow (n 
=30); or assigned to the hypertensive group (n = 56) where they received rat chow containing 
I3C (0.167 w/w %) for the remainder of the experiment (Table 2.1). Animal body weights 
were monitored weekly as specified in the University of Otago AEC approval conditions. The 
animals receiving the I3C diet had the hypertensive phenotype confirmed by blood pressure 
monitoring at regular 2 week intervals from the initiation of the diet (n = 25). SBP 
measurement for the normotensive rats were taken prior to termination (n = 20).  
 











n = 18 n = 12 n = 13 n = 9 n = 4 
 
Table 2.1 Duration of I3C (0.167 w/w %) diet administration used to optimise hypertensive status 





2.2.2 Confirmation of hypertensive phenotype 
SBP were obtained and recorded in normotensive and hypertensive animals using a non-
invasive tail pressure cuff and pulse transducer connected to a ML750 PowerLab unit 
(ADInstruments, Dunedin, New Zealand). Five sequential blood systolic blood pressure 
readings were taken for each rat and recorded using the LabChart v.6 Blood Pressure module 
(ADInstruments, Dunedin, New Zealand).  
2.2.3 Euthanasia of animals and isolation of the heart 
Animal body weights (BW) were obtained just before termination for experimental purposes 
at 18 - 22 weeks of age. The animals were anaesthetised using halothane in an induction 
chamber, and anaesthesia was maintained with a halothane nose cone. Following laparotomy, 
heparin (500 IU) was injected into the vena cava to prevent the formation of thrombotic 
occlusions and a rapid thoracotomy was then performed (Voucharas et al., 2011; Rossello et 
al., 2016). The heart was immediately excised and submerged in ice-cold Krebs-Henseleit 
buffer (KHB), weighed to obtain heart weight (HW) (Voucharas et al., 2011) and 
immediately perfused in a retrograde fashion via the aorta in the Langendorff mode. Non-
cardiac extraneous tissue was removed and subtracted from the initial HW measurement to 
give the final HW. The tibial bone was also measured from the right leg to obtain a reference 
tibial length (TL).  
 
2.3 Langendorff Experimental Protocol  
2.3.1 Langendorff set up 
Immediately, upon removal of the heart from the anaesthetised animal, the ascending aorta of 
the heart was perfused in a retrograde fashion by using a stainless steel cannula (Size 18) 
inserted to sit above the intact aortic valve. The cardiac vasculature was perfused through the 
coronary ostia with oxygenated (95% O2 / 5% CO2) KHB (mmol/L): NaCl 118, KCl 4.7, 
MgSO4 1.2, KH2PO4 1.23, NaHCO3 24, glucose 11.1, CaCl2 1.2 (pH 7.4) and maintained at 
37°C with a constant hydrostatic pressure (67.3 mmHg) (Adlam et al., 2005). Non-cardiac 
extraneous tissue was removed and a small incision made at the base of the pulmonary artery 
to allow coronary drainage. The left atria was removed and a deflated fluid filled balloon 
attached to a Piezo-resistive physiological pressure transducer (ADInstruments, Dunedin, 
New Zealand) was inserted into the left ventricle. A baseline sample of coronary effluent was 
collected for lactate dehydrogenase (LDH) analysis and the heart was then equilibrated for 20 
minutes before the balloon was gradually inflated until a constant end diastolic pressure 
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(EDP) between 6 - 10 mmHg was achieved (Voucharas et al., 2011). Hearts that failed to 
meet a minimal left ventricular developed pressure (LVDP) of 70 mmHg following balloon 
loading or hearts that failed to maintain baseline pressure prior to any manipulation were 
excluded from the protocol.  
2.3.2 Assessing ischaemia reperfusion injury  
Warm global ischaemia was achieved by halting perfusion to the heart for 30 minutes. 
Following this, the heart was reperfused and cardiac function was assessed for 60 min. 
Coronary flow rate (CFR) and haemodynamic data were measured at baseline and further 
measured at 5 and 10 mins following drug administration, and at 0, 5, 10, 15, 30, 45 and 60 
minutes’ post-ischaemia. Additional samples for LDH analysis were collected upon 
reperfusion and at 60 mins of reperfusion. LV haemodynamic data (LVDP derived from peak 
systolic pressure and end diastolic pressure, dP/dtmax and dP/dtmin) were recorded and 
analysed using peak analysis in the Blood Pressure Module of LabChart v.7 Pro 
(ADInstruments, Dunedin, New Zealand). For each time point a one-minute recording block 
was analysed. 
 
2.3.3 Drug dosing 
The vehicle control (pH 6 ddH2O) or oCOm-21 (1, 3 and 10 µM, pH 6 ddH2O) were 
administrated with the perfusate. Pre-ischaemic drug administration was initiated 10 minutes 
prior to ischaemic onset by infusing the drugs directly into the aortic cannula (Figure 2.1 A). 
The rate of drug administration was adjusted to the changes in CFR of each heart and 
controlled proportionally using a syringe driver (BAS MD-1020 Beehive Pump Controller, 
BASi, West Lafayette, USA). This method allowed the infusion delivery rate to be corrected 
with changes in CFR in order to deliver a fixed concentration of the test oCOm. Post-
ischaemic drug administration began directly upon reperfusion, and was adjusted according to 
the CFR as stated above over the following 10 minutes of dosing (Figure 2.1 B).  
2.3.4 ODQ pilot study protocol 
LV peak systolic pressure, end diastolic pressure and CFR were measured in hypertrophic 
hearts (n = 3). In protocol one ODQ (5 or 10 µM) was infused alone for 10 minutes. Between 
each protocol the heart was washed out for 10 minutes by perfusion with KHB. In the second 
protocol the same hearts were infused with ODQ (5 or 10 µM) and oCOm-21 (3 µM) at the 
same time for 10 minutes. In the third protocol ODQ (5 or 10 µM) was infused for 20 minutes 
with the infusion of oCOm-21 (1 or 3 µM) initiated at 10 minutes following the start of the 
protocol and continued for 10 minutes.  
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Figure 2.1 Langendorff protocol for assessing ischaemia reperfusion injury following (A) pre-infusion and 
(B) pre-ischaemic infusion and infusion upon reperfusion in Cyp1a1-Ren2 rat hearts. Eppendorf tubes 
represent LDH collected points and arrows represent the recorded coronary flow measurement time points 
(minutes) during the study period.   
 
2.3.5 Sectioning of the heart for histological analysis  
At the conclusion of the I/R protocol animal hearts were immediately prepared for histology. 
The apical portion of the heart was cut approximately 3 mm superior from the apex and 
maintained in 10 % neutral buffered formalin (NBF; LabServ, Thermo Fisher, New Zealand) 
for 24 hours and stored in 95 % ethanol thereafter. Tissue processing and wax embedding was 
carried out by the Histology Service Unit, Department of Pathology, University of Otago, NZ. 
Tissues were dehydrated with ethanol (70 - 100%), before immersion in paraffin at 65 °C 
under vacuum and set into paraffin blocks, for microtome sectioning at 4 µm, and mounting 
on slides. Sections were dried at 60°C for 1 hour and stored at room temperature until 
staining.  
2.4 Histological and Immunohistochemical Studies    
2.4.1 Myocardial fibrosis assessment   
Picrosirius red staining was performed to quantify the levels of fibrotic deposition (collagen I 
and III) within cardiac tissue. Sections were dewaxed with xylene and rehydrated through a 
series of alcohol washes (100 - 50%) to water. Sections were incubated in 0.1% picrosirius 
red for 1 hour at room temperature. Following incubation, sections were rinsed initially in 
water and then acidified water (0.1 N). The sections were then counterstained with 0.05% 
Fast Green for 60 seconds. Immediately following counterstaining, sections were rapidly 
dehydrated (50% - 100%), placed in xylene and cover-slipped using DPX mountant.  
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2.4.1.1 Quantification of fibrosis 
Digital images of each field of view across the entire section were taken at 10× magnification 
using a Nikon Eclipse Ni-E upright microscope using a proprietary Digital Sight DS-U3 
camera (Nikon Corporation, Tokyo, Japan). An entire image of the whole cardiac section was 
produced by stitching together the 70 – 120 individual fields with NIS-Elements imaging 
software (version 4.13). Quantitative analysis of total left ventricular fibrosis was conducted 
by analysing the proportion of picrosirius red staining in each tissue section using the Fiji 
Image J software (version 2.0.0-rc-69/1.52n). Each image was converted to a red, green, blue 
stack; images were analysed in the green channel. The region of interest was selected and 
using the threshold tool the ratio of collagen stained (red) pixels to total pixels was calculated 
in each cardiac section subtracting background. Two independent observers unrelated to the 
project were trained in the protocol and analysed three images each to provide an unbiased 
reference standard and ensure reporting consistency and accuracy.  
2.4.2 Myocardial necrotic cell death assessment  
Necrotic cell death was assessed using the lactate dehydrogenase (LDH) activity assay. A 
reaction mixture (pyruvate 4.63 mM, phosphate buffer 38.6 mM, pH 7.5 and NADH 0.139 
mM) was added to all wells of a 96 well plate, except for a control well in which equal 
volumes of ddH2O was added to the wells. The 96 well plate was placed in the reading 
chamber of a SpectraMax i3X Plate Reader (Molecular Devices, San Jose, USA) at 25ºC for 1 
minute to warm. Coronary effluent samples (40 µL) were pipetted in triplicate in the wells, 
and after the plate was shaken to ensure mixing, absorbance readings at λ =340 nm were 
recorded at 30, 60 and 90 seconds.  
 
LDH activity (U/L) was calculated using the equation: 
!"#	%&'()('*	(,/!) = ∆1340	×		67	×		10006.22	×		<7	×		!=  
∆A340  = Change in absorbance per minute (90 seconds – 30 seconds) 
TV  = Total reaction mixture volume  
6.22  = Millimolar absorptivity of NADH at 340 nm 
SV  = Sample volume 
LP  = Light path  




2.4.3 Myocardial apoptosis assessment 
Apoptotic cell death was assessed by detecting and labelling DNA strand breaks within 
cardiac sections using the ApopTag® Peroxidase In Situ Apoptosis Detection Kit (Millipore, 
Billerica, USA).  The DNA strand breaks were detected by enzymatically labelling the free 3'-
OH termini with modified nucleotides. Sections were dewaxed with xylene and rehydrated 
through a series of alcohol washes (100 - 50%) to phosphate buffered saline (PBS). Sections 
were incubated with Proteinase K (20 µg/Ml; 20 minutes) to unmask epitopes and rinsed in 
ddH2O. Sections were incubated in PBS containing 3% hydrogen peroxide (H2O2) (10 
minutes) to block endogenous peroxidases for staining and then washed in PBS. The sections 
were then incubated with the ApopTag kit Equilibration buffer (75 µL/5 cm2; 15 minutes) in a 
humidified chamber at room temperature. Finally, the sections were then incubated with 
working strength terminal deoxynucleotidyl (TdT) enzyme (70% reaction buffer with 30% 
TdT enzyme) (55 µL/5 cm2) for 60 minutes in a humidified chamber at 37ºC. The reaction 
was then terminated by incubating the sections with pre-warmed working strength stop/wash 
buffer (1 mL stop/wash buffer: 34 mL dH2O) for 30 minutes in a humidified chamber at 37ºC. 
The sections were washed in PBS prior to the application of anti-digoxigenin antibody 
conjugate (65 µL/5 cm2); sections were incubated for 30 minutes at room temperature and 
then washed again in PBS. Binding of the anti-digoxigenin antibody to the peroxidase 
reporter molecule enzymatically generates a localised stain site for chromogenic substrate 
products such as the A 3,3-diaminobenzidine (DAB) Substrate Kit (Vector Laboratories, 
Burlingame, USA).  The DAB solution consisting of substrate buffer (0.04 mL, pH 7.5), DAB 
(0.1 mL) and H2O2 (0.04 mL) in 5 mL of ddH2O was applied to the slides under low light 
conditions. Sections were incubated in the DAB solution for 10 minutes and rinsed in dH2O 
for 5 minutes. Sections were then counterstained with Gills haematoxylin (10 seconds) 
followed by washing under running tap water. Sections were then dehydrated in a series of 
alcohol washes (50% - 100%), cleared in xylene and coverslipped using DPX mountant. 
2.4.3.1 Quantification of apoptosis  
A large digital image of 40 - 60 images from the LV anterior wall containing endocardium, 
myocardium and epicardium was taken for each cardiac section at 40× magnification using 
the Eclipse Ni-E upright microscope (Nikon Corporation, Tokyo, Japan) and stitched together 
using NIS-Elements imaging software (version 4.13). Images were analysed in Fiji Image J 
software (version 2.0.0-rc-69/1.52n). Using a grid, a minimum of ten 0.125 mm2 fields were 
randomly selected per cardiac section and analysed as seen in Figure 2.2. The total number of 
ApopTag positive nuclei (brown) and ApopTag negative nuclei (purple) were manually 
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counted in each field. The total number of analysed fields were averaged and presented as a 
percentage of ApopTag positive cells to total cells. To minimise bias and ensure reporting 
accuracy two independent observers unrelated to the project both analysed a known set of ten 
fields and the results were compared against that of the primary researcher. 
 
 
Figure 2.2 Representative image of the 0.125 mm2 grid overlaying a large image of the left ventricular 
anterior wall for quantification of apoptosis following ApopTag immunohistochemistry. Image analysed in 
Image J. Red box represents one standard 40× magnification image. Scale bar represents 0.10 mm.  
 
 
2.5 Statistical Analysis  
SBP and the degree of fibrosis were analysed using a one-way analysis of variance 
(ANOVA). Haemodynamic data (LVDP, dP/dt max, dP/dt min and CFR) were analysed using 
a two-way repeated measures ANOVA, comparing the effect of treatment against time post-
ischaemia. LDH was analysed using a two-way repeated measures mixed model analysis 
assessing LDH activity upon reperfusion and 60 minutes’ reperfusion against baseline values. 
All multiple comparisons were analysed with a Bonferroni post-hoc analysis. Linear 
regressions were used to assess correlations between the inotropic response to percentage 
recovery of LVDP at 60 minutes. All data was analysed using GraphPad Prism software 
version 8.0 (GraphPad Software Inc., La Jolla, USA). Data are expressed as mean ± standard 
error of the mean (SEM). Statistical significance was set at P < 0.05.  
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3. Results  
3.1 Left Ventricular Hypertrophy Development  
Systolic blood pressure (SPB) recordings (Figure 3.1 A) confirmed that inclusion of I3C 
(0.167 %) in the oral diet resulted in a persistent elevation in SPB by week 2 from baseline 
recordings (183.2 ± 8.71 against 120.5 ± 3.55 mmHg respectively; P < 0.001). Continuation 
of the IC3 diet, increased SBP by 79.7 % at termination compared to the standard rat chow 
(without I3C) at the 18 – 22 weeks termination points (177.7 ± 5.69 versus 98.9 ± 4.06 




Figure 3.1 Systolic blood pressures (SBP) measurements (mmHg) in male Cyp1a1-Ren2 rats fed indol-3-
carbinol (I3C). (A) sequential measurements taken prior to the initiation of the diet and at 2 week intervals 
until termination at weeks 8, 10 or 12. Data represents mean ± SEM; n = 8 – 20 animals/time point post 
diet initiation; ****P < 0.0001 SBP against baseline. (B) Confirmation of SBP elevation at termination in 
the hypertensive group fed the I3C diet versus the normotensive group. Data represents mean ± SEM; n = 
20 – 45 individual animals/group. ****P < 0.0001 SBP in rats fed the I3C diet against rats fed standard rat 
chow diet minus I3C.  
 
Induction of chronic malignant HTN in the I3C animals resulted in a significant increase in 
heart weight development determined as a ratio of heart weight (HW) to tibial length (TL) 
and as HW to body weight (BW) at termination. The length of time on the I3C diet (8 – 12 
weeks) did not have any significant impact on the HW/TL ratio or the HW/BW ratio (Table 
3.1). Hearts from hypertensive rats were separated into two groups based on the hypertrophic 
index of HW:TL ratio as < 50 mg of HW/mm TL and ≥ 50 mg of HW/mm TL. Cardiac 
hypertrophy was confirmed (Figure 3.3 A) as significant increases from 32.28 ± 1.18 mg/mm 
in the normotrophic group to 45.2 ± 0.88 mg/mm in the moderately hypertrophic group (< 50 
mg/mm) (P < 0.0001) and 58.70 ± 1.11 mg/mm in the severely hypertrophic group (≥ 50 
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mg/mm) (P < 0.0001). Further, a significant increase in heart weight of 29.9% was observed 
between the moderately and severely hypertrophic groups (P < 0.0001; Figure 3.3 A).  
 
Left ventricular cardiac fibrosis (including both interstitial and perivascular fibrosis), 
identified using picrosirius red staining, increased by 74.2 % in the moderately hypertrophic 
group (P < 0.0001) and 75.3 % the severely hypertrophic group (P < 0.0001) when 
comparing against the normotrophic control group (8.52 ± 0.64 and 8.57 ± 0.47 versus 4.89 ± 
0.3 mg/mm, respectively) (Figure 3.3 C and Figure 3.2). The length of time on the I3C diet 8 




Figure 3.2 Representative images of cardiac fibrosis. Transverse cardiac sections stained with picrosirius 
red and fast green counter stain. Images show the degree of cardiac hypertrophy in normotrophic hearts 
from non-hypertensive Cyp1a1-Ren2 rats and moderately hypertrophic and severely hypertrophic hearts 











Figure 3.3 Degree of cardiac hypertrophy in Cyp1a1-Ren2 rats. Hypertrophy was graded by the ratio of (A) heart weight (HW) to tibial length (TL) (mg/mm), (B) HW (g) / 
100g body weight at termination and (C) percentage of left ventricular (LV) fibrosis. Groups represent hearts from non-hypertensive animals (NH) and hypertensive animals 
(H) induced by I3C (0.167 % w/w). Hearts from hypertensive rats were subdivided according to the degree of hypertrophic heart development; moderate hypertrophy 
correlating with H < 50 mg/mm and severe hypertrophy correlating with H ≥ 50 mg/mm. Representative micrographs of transverse cardiac sections Data represents mean ± 
SEM; (A and B) n = 16 – 26 animals/group, (C) n = 12 – 13 animals/group. ****P < 0.0001 compared to non-hypertensive control. ####P < 0.0001 hypertensive < 50 
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  Time on indol-3-carbinol (0.167 %) diet 
 Normotensive control  
(no I3C) 
n = 26 
Group 1  
(8 weeks) 
n = 18 
Group 2  
(9 weeks) 
n = 12 
Group 3  
(10 weeks) 
n = 13 
Group 4  
(11 weeks) 
n = 9 
Group 5  
(12 weeks) 
n = 4 
HW/TL ratio 34.25 ± 1.13 mg/mm 49.85 ± 2.10 mg/mm 52.95 ± 3.50 mg/mm 48.51 ± 2.03 mg/mm 52.49 ± 2.58 mg/mm 57.12 ± 3.29 mg/mm 
HW/BW ratio 0.361 ± 0.15 g/100g 0.687 ± 0.34 g/100g 0.604 ± 0.03 g/100g 0.562 ± 0.02 g/100g 0.617 ± 0.03 g/100g 0.647 ± 0.03 g/100g 
LV fibrosis (%) 4.89 ± 0.3 % 7.93 ± 0.81 % 8.83 ± 0.69 % 7.53 ± 0.40 % 9.92 ± 0.86 % 
 
Table 3.1 Breakdown of cardiac hypertrophy parameters against time on the indol-3-carbinol diet in hypertensive Cyp1a1-Ren2 rats. Data represents mean ± SEM. Data 





3.2 Pre-ischaemic Response to oCOm-21 
Left ventricular developed pressure was increased following infusion of the pre-ischaemic 
protective agent, oCOm-21, in both normotrophic and hypertrophic hearts (Figure 3.4 and 
Figure 3.5). In normotrophic hearts, vehicle control did not increase LVDP values while 
oCOm-21 infusion produced significant sustained increases in LVDP with 1 and 3 µM (P < 
0.0001) (Figure 3.4 A). The initial elevation in LVDP following 10 µM of oCOm-21 was 
significantly increased relative to vehicle control (P < 0.01), however, this elevation was not 
sustained throughout the 10 minute dosing period, with LVDP returning towards the pre-
infusion baseline values (Figure 3.4 A). In the hypertrophic hearts, vehicle control and DB-21 
infusion did not elevate LVDP (Figure 3.4 B). A modest increase in LVDP was observed with 
the infusion of 1 µM oCOm-21 (P < 0.0001) while infusion with the higher concentrations of 
oCOm-21, (3 and 10 µM), led to larger LVDP value increases (P < 0.0001) (Figure 3.4 B). 
The sample trace provided (Figure 3.5) shows the sustained inotropic response following 3 
µM oCOm-21 infusion in a hypertrophic heart and the subsequent return to the pre-infusion 
baseline following the termination of infusion and perfusion washout of oCOm-21. 
	
 
Figure 3.4 Pre-ischaemic LVDP response in (A) normotrophic and (B) hypertrophic hearts. LVDP 
percentage change from pre-infusion baseline. Hearts were treated with: vehicle control, or oCOm-21 at 1, 
3 and 10 µM for 10-minutes prior to the initiation of ischaemia. Data represents mean ± SEM; (A) n = 3 – 5 
animals/group, (B) n = 7 – 11 animals/group. ****P < 0.0001 and **P < 0.01 compared to vehicle control, 












Figure 3.5 Sample trace of systolic and diastolic pressure (mmHg) during and following infusion of (A) oCOm-21 (3 µM) and (B) vehicle control for 10 minutes in an 




3.3 Haemodynamic Recovery Following Ischaemia  
3.3.1 Left ventricular developed pressure 
oCOm-21 improved LVDP recovery at reperfusion following a 30 minute warm global 
ischaemic event in both normotrophic and hypertrophic hearts (Figure 3.6). In the 
normotrophic hearts oCOm-21 (1 and 3 µM) produced an overall significant improvement of 
LVDP compared to the vehicle control treated hearts (P < 0.01) (Figure 3.6 A). Furthermore, 
pre-ischaemic infusion of oCOm-21 (1, 3 and 10 µM) had improved the LVDP recovery at 
the 60 minute time point of reperfusion ranging from 56.37 % in the 1 µM oCOm-21 treated 
hearts to 102.26 % in the 3 µM treated hearts (Figure 3.6 B).  
 
The combined data from all hypertrophic hearts (inclusive of both < 50 mg/mm and hearts ³ 
50 mg/mm groups) showed that the protective effect of oCOm-21 was attenuated when 
compared to normotrophic hearts (Figure 3.6 B). However, 3 µM of oCOm-21 still produced 
a significant recovery in LVDP during reperfusion, greater than both vehicle control and DB-
21 (P < 0.01). Importantly no significant difference was obtained between vehicle control and 
the non-CO releasing version of oCOm-21, DB-21.  
 
In the hearts classified as moderately hypertrophic (< 50 mg/mm), 3 µM of oCOm-21 (72.8 ± 
24.55 %) produced the greatest benefit for LVDP recovery at 60 minutes followed by 10 µM 
(39.22 ± 10.02 %) while producing overall significance throughout reperfusion relative to 
vehicle control (P < 0.05) (Figure 3.6 C). In the severely hypertrophic hearts (³ 50 mg/mm) 
only 10 µM of oCOm-21 (35.66 ± 5.23) improved LVDP at 60 minutes against vehicle 
control (26.22 ± 6.31 %) (Figure 3.6 D). Further, 10 µM of oCOm-21 produced significant 
haemodynamic improvement over the entire reperfusion period against vehicle control and 
the lesser 1 µM concentration of oCOm-21 (P < 0.05) (Figure 3.6 D).  
 
Infusion of oCOm-21 (1 and 3 µM) immediately prior to ischaemia, with a subsequent 
infusion at the start of reperfusion, did not offer protection against I/R injury in normotrophic 
hearts (Figure 3.7). When compared to vehicle control (59.84 ± 12.28 mmHg) recovery in the 
pre- and post-treated hearts at 60 minutes of reperfusion was reduced by 32.45 % with a 1 µM 






Figure 3.6 LVDP recovery in pre-ischaemic treated (A) normotrophic and (B) hypertrophic hearts. 
Recovery during 60 minutes’ reperfusion (normalised to baseline) following a 30 minute warm global 
ischaemic episode. Hearts were treated with: vehicle control, or oCOm-21 at 1, 3 and 10 µM for 10 
minutes. Hypertensive hearts were subdivided according to the degree of hypertrophic heart development 
as determined by heart weight (mg) to tibial length (mm) (mg/mm); (C) moderately hypertrophic (< 50 
mg/mm) and (D) severely hypertrophic (≥ 50 mg/mm). Data represents mean ± SEM; (A) n = 3 – 5 
animals/group, (B) n = 7 – 11 animals/group, (C) n = 2 – 5 animals/group, (D) n = 3 – 6 animals/group.  
***P < 0.001 and **P < 0.01 compared to vehicle control, YYYP < 0.001 compared to DB-21,YP < 0.05 
compared to DB-21, ##P < 0.01 and #P<0.05 between oCOm-21 1 and 3 µM, dP < 0.05 between oCOm-21 






Figure 3.7 Combination pre-ischaemic and post-ischaemic treatment with oCOm-21 in normotrophic 
hearts. Values from baseline, during 10 minutes of treatment infusion prior to 30 minutes of warm global 
ischaemia and recovery during 60 minutes of reperfusion with 10-minutes of treatment upon reperfusion. 
Hearts were treated with: vehicle control, or oCOm-21 at 1 and 3 µM. Data represent mean ± SEM; n = 3 
animals/group.  
 
3.3.2 Coronary flow rate  
Pre-ischaemic infusion of oCOm-21 (1, 3 and 10 µM) produced rapid increases in CFR by 5 
minutes in all normotrophic, moderately hypertrophic and severely hypertrophic hearts 
(Figure 3.8). By 60 minutes of reperfusion, oCOm-21 infusion produced a 95.3 % recovery, 
to pre-ischaemic baselines values, in the 3 µM oCOm-21 treated hearts and a 84.2 % recovery 
with 10 µM of oCOm-21 against a 73.1 % recovery in the vehicle control group in 
normotrophic hearts (Figure 3.8 A). In moderately hypertrophic hearts, only 3 µM of oCOm-
21 (69.8 %) improved the return of CFR beyond the 41.1 % recovery in the vehicle control 
treated hearts (Figure 3.8 B). Administration of oCOm-21 at all concentrations (1, 3 and 10 
µM) in the severely hypertrophic hearts marginally improved the recovery of CFR to baseline 
values from 47.0 – 56.5 % at 60 mins of reperfusion against vehicle control (40.6 %) (Figure 






Figure 3.8 Coronary flow rate in (A) normotrophic, (B) moderately hypertrophic (< 50 mg/mm) and (C) 
severely hypertrophic (≥ 50 mg/mm) hearts during 60 minutes of reperfusion following a 30 minute warm 
global ischaemic episode. Hearts were treated with: vehicle control, DB-21 and oCOm-21 at 1, 3 and 10 
µM for 10 minutes prior to the initiation of ischaemia. Data represents mean ± SEM; (A) n = 3 – 5 
animals/group, (B) n = 2 – 5 animals/group, (C) n = 3 – 6 animals/group. 
 
3.3.4 Heart rate  
No change in heart rate was observed during the 10-minute infusion period of 1 and 3 µM 
oCOm-21 in normotrophic, moderately hypertrophic or severely hypertrophic hearts (Figure 
3.9). However, a 10-minute infusion of 10 µM oCOm-21 did decrease baseline heart rate 
indices by 18 % in normotrophic, 56.9 % in moderately hypertrophic; and 26.7 % in severely 
hypertrophic hearts. Heart rates over the reperfusion period (0 - 60 minutes) were also 
assessed and overall significant differences were observed between the treatment groups. In 
normotrophic and moderately hypertrophic hearts, the 1 and 3 µM oCOm-21 concentrations 
produced rapid and sustained recovery of heart rate, with values returning to baseline values 
by 60-minutes reperfusion (Figure 3.8 A and B). The 1 and 3 µM oCOm-21 concentrations 
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were more efficacious than 10 µM oCOm-21 (P < 0.01) (Figure 3.9 A and B). Furthermore, 
10 µM of oCOm-21 significantly attenuated the recovery of heart rate over time during the 
reperfusion period in the moderately hypertrophied hearts, when compared to the vehicle 
control (P < 0.01). No significant differences in heart rate recovery were seen in any of the 




Figure 3.9 Heart rate in (A) normotrophic, (B) moderately hypertrophic (< 50 mg/mm) and (C) severely 
hypertrophic (≥ 50 mg/mm) hearts during 60 minutes of reperfusion following a 30 minute warm global 
ischaemic episode. Hearts were treated with: vehicle control, DB-21, and oCOm-21 at 1, 3 and 10 µM for 
10 minutes prior to the initiation of ischaemia, additionally hypertrophic hearts were treated with the non-
CO releasing derivative of oCOm-21. Data represents mean ± SEM; (A) n = 3 – 5 animals/group, (B) n = 2 
– 5 animals/group, (C) n = 3 – 6 animals/group. **P < 0.01 compared to vehicle control, dddP < 0.001 and 





3.3.5 Left ventricular dP/dt  
Post ischaemic dP/dtmax recovery was improved in normotrophic hearts with the pre-
ischaemic addition of oCOm-21 (Figure 3.10 Ai). Between oCOm-21 (3 µM) and vehicle 
control a significant increase in dP/dtmax was observed at the 45 and 60 minute reperfusion 
points (P < 0.05) (Figure 3.10 Ai). An increase in dP/dtmin was also observed between oCOm-
21 (3 µM) and vehicle control at 30, 45 and 60 minutes during reperfusion (P < 0.05) (Figure 
3.10 Aii). Further, increasing the administered oCOm-21 concentration from 1 and 3 µM, 
increased dP/dtmin at the 45 and 60 minute reperfusion points (P < 0.05). No significant 
differences in dP/dtmax or dP/dtmin were obtained as a consequence of oCOm-21 administered 







Figure 3.10 Left ventricular pressure change during isovolumetric contraction as measured by dP/dtmax (i) 
and dP/dtmin (ii) in (A) normotrophic, (B) moderately hypertrophic (< 50 mg/mm) and (C) severely 
hypertrophic (≥ 50 mg/mm) hearts during 60 minutes of reperfusion following a 30 minute warm global 
ischaemic episode. Hearts were treated with: vehicle control, DB-21 10 µM and oCOm-21 at 1, 3 and 10 
µM for 10 minutes prior to the initiation of ischaemia. Data represents mean ± SEM; (A) n = 3 – 5 
animals/group, (B) n = 2 – 5 animals/group, (C) n = 3 – 6 animals/group. *P < 0.05 compared to vehicle 




3.4 Quantification of Myocardial Damage 
3.4.1 Necrotic cell death 
LDH activity increased against the respective baseline in all the immediate post-ischaemic 
coronary effluents collected from the untreated (vehicle control) normotrophic and 
hypertrophic perfused hearts (Figure 3.11 A). While indicative of enzyme leakage in damaged 
myocardium, this value was not significant however when analysed using a repeated 
measures 2-way ANOVA.  In normotrophic hearts, treated with oCOm-21 prior to ischaemia, 
however no significant increases in LDH activity from baseline values was seen in any of the 
treatment groups upon reperfusion (0 – 1 minutes) or at the end of reperfusion (60 minutes) 
(Figure 3.10 A).  
 
LDH activity was not significantly increased either from the baseline values in moderately or 
severely hypertrophic hearts infused with vehicle control or 3 and 10 µM of oCOm-21 against 
respective baselines (Figure 3.11 B and C). In both the moderately and severely hypertrophic 
hearts however significant increases were obtained in the 1 µM oCOm-21 treated hearts (P < 
0.05 against respective baselines; Figure 3.11 B and C). In the moderately hypertrophic hearts 
LDH activity in all treatment groups had returned to baseline values by 60 minutes of 
reperfusion, while the 1 µM oCOm-21 treated hearts in the severely hypertrophic group 
remained elevated above baseline (Figure 3.11 B and C). Furthermore, DB-21 did not lead to 
a significant increase in LDH activity during the first minute of reperfusion with comparable 
activity to the vehicle control.  
 
Combination treatment in normotrophic hearts infused with oCOm-21 (1 and 3 µM), prior to 
ischaemia and immediately upon reperfusion, also prevented any significant increase in LDH 
effluent activity immediately upon reperfusion and values in these coronary perfusates 




Figure 3.11 Lactate dehydrogenase activity from the coronary effluent of (A) normotrophic, (B) moderately hypertrophic (< 50 mg/mm) and (C) severely hypertrophic (≥ 
50 mg/mm) hearts. Collections at baseline (upon placement on the Langendorff rig), immediately upon reperfusion (0 – 1 minutes) and at 60 minutes of reperfusion. Hearts 
were treated with: vehicle control, DB-21 10 µM, and oCOm-21 at 1, 3 and 10 µM for 10 minutes prior to the initiation of ischaemia. (D) Represents normotrophic hearts 
treated with vehicle control or oCOm-21 at 1 and 3 µM for 10-minutes prior to ischaemia and immediately upon reperfusion. Data represents mean ± SEM; (A) n = 3 – 5 
animals/group, (B) n = 2 – 5 animals/group, (C) n = 3 – 6 animals/group, (D) n = 3 animals/group. *P < 0.05 against baseline value.  
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3.4.2 Apoptotic cell death 
ApopTag – DAB staining was restricted to nuclear components under microscopic analysis. 
Analysis of the ApopTag immunohistochemical staining in the normotrophic hearts showed 
pre-treatment with 1, 3 and 10 µM of oCOm-21 reduced the percentage of ApopTag positive 
cells by 71.9 %, 50.7 % and 33.7 %, respectively against the control treated hearts following 
I/R injury (Figure 3.12 A). ApopTag analysis in the hypertrophic hearts revealed the control 
group had a larger percentage of ApopTag positive cells than in the normotrophic hearts.  Pre-
treatment with 1, 3 and 10 µM of oCOm-21 resulted in a reduction of the percentage of 
ApopTag positive cells by 83.87 % (P < 0.01), 89.42 % (P < 0.01) and 74.22 % respectively, 











Figure 3.12 ApopTag immunohistochemistry of cardiac sections. A-E show representative images of 
ApopTag in hypertrophic hearts: (A) negative control; (B) control; (C) oCOm-21 1 µM; (D) oCOm-21 3 
µM; and (E) oCOm-21 10 µM. Images were captured at 40× magnification and scale bars represent 50 µm. 
Arrows depict ApopTag positive cells. (F) and (G) demonstrate quantification of total ApopTag-positive 
cells as a percentage of total cells.  Sections were stained with DAB and counterstained with Gill’s 









3.5 ODQ Pilot Study 
ODQ infusion (10 minutes) alone in the hypertrophic hearts reduced LV systolic pressure 
from the respective baseline values. 10 µM of ODQ produced a 56% reduction (n = 1) while 5 
µM ODQ produced a 8% reduction (n = 2) (Figure 3.14 A). Infusion of ODQ at either 
concentration (5 and 10 µM) however failed to block the oCOm-21 (3 µM) induced increase 
in systolic pressure (36% and 29% increase from the baseline values; n = 2) (Figure 3.14 B). 
Addition of 1 µM of oCOm-21 at 10 minutes during continual infusion of ODQ (5 µM; 20 
minutes), also produced a 15% increase in LV systolic pressure (compared to the pre-oCOm-
21 infusion baseline) (Figure 3.13 and Figure 3.14 B). Interestingly the infusion of the 1 µM 
dose of oCOm-21 in the presence of ODQ (5 µM) also resulted in an adverse 67% increase in 
the diastolic pressure (Figure 3.14 B). The changes in the LV systolic and diastolic pressure 
with the addition of the 1 µM oCOm-21 under these conditions were accompanied by an 
increase in the CFR (Figure 3.13). The increase in systolic and diastolic pressure was also 
observed when 3 µM of oCOm-21was infused in the presence of 5 µM ODQ under the same 
condition as stated above (28% increase and 110% increase, respectively) (Figure 3.14 B). In 
contrast, the higher dose of ODQ (10 µM) infused for 20 minutes blocked any increase in 
systolic and diastolic pressures evoked by the addition of 3 µM of oCOm-21 at 10 minutes 
































Figure 3.13 Sample trace of systolic and diastolic pressure (mmHg) during infusion of the highly selective irreversible heme-site inhibitor of soluble guanylyl cyclase, 














Figure 3.14 ODQ pilot study. Systolic and diastolic left ventricular pressure (mmHg) changes in 3 
individual hypertrophic hearts following infusion of (A) ODQ alone for 10 minutes, (B) ODQ with oCOm-





Figure 3.15 Linear correlation of the oCOm-21 (1, 3 and 10 µM) pre-ischaemic inotropic response against 






















































































ODQ (5 µM) and oCOm-21 (3 µM)




























































4.1 Model of Left Ventricular Hypertrophy Development  
This study was able to successfully establish a non-invasive model of LVH development in a 
Cyp1a1-Ren2 transgenic rat through an adaptive response to HTN haemodynamic pressure 
overload. The induction of malignant HTN in the Cyp1a1-Ren2 rat with I3C has been well 
established in previous research, with 0.167 - 0.6 % w/w I3C dosing inducing SBPs > 180 
mmHg (Heijnen et al., 2011; Howard et al., 2011; Leader et al., 2018). The induced Cyp1a1-
Ren2 model used in this study was chosen as it closely imitates the development of LVH in 
the humans suffering prolonged uncontrolled HTN. The model also has distinct advantages 
over other LVH models, such as the spontaneously hypertensive rat and the m(Ren2)27 rat in 
that the induction time-point, rate and duration of HTN can be regulated in a dose-dependent 
manner by the inclusion of a set dose of I3C in the rat chow, and by extension the severity of 
LVH can be controlled (Patten and Hall-Porter, 2009; Janssen et al., 2012; Heijnen et al., 
2014). Equally, the maladaptive LV remodelling obtained through the sustained induction of 
hypertension in the Cyp1a1-Ren2 reflects the common clinical manifestation of LVH far 
better than invasive methods involving aortic banding or renal artery occlusion (Wiesel et al., 
1997; Patten and Hall-Porter, 2009; Richards et al., 2019).  
 
The majority of Cyp1a1-Ren2 rat studies published to date have employed concentrations of 
I3C ≥ 0.3 % w/w in the diet for a maximum period of six weeks (Heijnen et al., 2011; 
Howard et al., 2011; Mitchell et al., 2013; Zhou et al., 2018). The dose of I3C chosen in this 
study was based on previous research work conducted by our laboratory group where a 14 
week dosing period with a lower concentration of 0.167 % w/w significantly elevated SPB, 
induced cardiac hypertrophy and interstitial cardiac fibrosis without adversely compromising 
animal welfare (Leader et al., 2018; Leader et al., 2019). Additionally, our group showed that 
male Cyp1a1-Ren2 rats fed I3C for two and three months suffered a time-dependent decrease 
in cardiac LV ejection fractions measured using echocardiography (Leader et al., 2019). 
Heijnen and colleagues have shown that the induction of HTN with 0.3 % w/w IC3 for 4 
weeks in young Cyp1a1-Ren2 rats, leads to inward concentric ventricular remodelling. 
increased LV wall thickness and decreased cardiac output (Heijnen et al., 2014). 
Echocardiography was unable to be performed in this study due to the need to anaesthetise 
each animal during the ultrasound procedure. As extensive use of gaseous anaesthetics has 
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been associated with both positive and negative impacts on the preconditioning signalling 
pathway of interest in the study, it was considered necessary to avoid any confounding 
artefacts (Weber and Schlack, 2008).  
 
The present study validated the previous findings by Leader et al. demonstrating that 0.167 % 
w/w I3C in the rat chow diet substantially elevated SPB (183.2 ± 8.71 mmHg) by week 2. 
SBP remained elevated in the rats fed I3C until termination. Prolonged elevated SPB over 8 - 
12 weeks was associated with the development of LVH, confirmed by increases in HW and 
by increased in LV fibrosis. The percentage of LV fibrosis obtained in the hypertensive rats in 
the present study matches previously conducted study data by our research group where I3C 
(0.167 % w/w) dosing for 3 months resulted in a percentage of LV fibrosis of 8.8 % (Leader 
et al., 2019). These results are in contrast to Peters and colleagues who reported that 
administration of a lower oral dose of I3C (0.125 % w/w) for 12 weeks did not increase 
cardiac fibrosis in Cyp1a1-Ren2 rats despite accompanying increases in the SBP and HW 
(Peters et al., 2009). The increased heart weights obtained correlated to a HW/TL ratio of less 
than 0.25 g/cm, with the study classifying this as moderate cardiac hypertrophy (Peters et al., 
2009). Equally, an earlier study by Peters et al. showed that while this lower dose of I3C had 
increased mean arterial blood pressure, the authors failed to show any significant evidence of 
hypertensive renal injury presenting as vasculopathy or glomerulosclerosis (Peters et al., 
2008). Our study observed an increased HW/TL ratio of 0.57 g/cm in the rats fed the 0.167 % 
w/w I3C diet for 12 weeks. While a reason for the disparity in HW is not clear it can be 
hypothesised that the difference may be due to the lower dose of I3C used in the Peters et al. 
study (0.125 % w/w) compared to the dose used in the present study (0.167 % w/w). 
Furthermore, the I3C diet was initiated in 15 week old rats in the Peters et al. study whereas 
the present study initiated the diet at 8 weeks of age. 
 
A small variation between the present study and the earlier publication by Leader and 
colleagues, exists in the degree of LV fibrosis in the normotensive rats. The present study 
found a higher value of 4.89 % in the untreated rats whereas the previous study reported 2.4 
% (in 24 week old normotensive rats) (Leader et al., 2019). It was noted that the baseline 
maintenance rat diet provided by the University of Otago animal facility had changed from a 
Speciality Feeds rat chow to a Harlan’s formulated rat chow in the interval between the two 
studies. It is possible used this newer diet may have unwittingly contained low levels of a 
Cyp1a1 inducer. This discrepancy merits further investigation as the normotrophic hearts in 
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these non-Cyp1a1 induced transgenic animals were considered to be mildly fibrotic. If upon 
further investigation, the normotrophic hearts are also confirmed to have a pre-existing level 
of cardiomyopathy, this finding would extend out the reach of the present study given oCOm-
21 significantly improved LV haemodynamic parameters in these hearts sourced from non-
hypertensive animals.  
 
While the duration (8 - 12 weeks) on the I3C diet produced an increase in the HW/TL ratio, 
no significant differences were noted in the degree of the cardiac hypertrophy (HW/TL, 
HW/BW and % of LV fibrosis) measured between groups. Within cage difference in HW and 
% of LV fibrosis were observed among litter mates. The absence of difference may be 
explained by differences in the amount of I3C diet individually consumed by each animal 
during the dosing period. However, as rats were housed in groups of 3 – 5 per cage it was 
impossible to dissect out the amounts consumed by individual animals.  
 
4.2 Post-ischaemic Haemodynamic Recovery  
This study examined the effect of a novel organic carbon monoxide donor, oCOm-21, on LV 
haemodynamic parameters, CFR, and myocardial cell damage in normotrophic and 
hypertrophic rat hearts from Cyp1a1-Ren2 transgenic rats. The administration of oCOm-21 
immediately prior to ischaemia was chosen to comply with current clinical cardioplegic 
perfusion techniques employed during cardiac surgical interventions involving CPB. In this 
setting, there is an opportunity to prophylactically treat the heart to reduce the morbidities and 
mortality associated with myocardial I/R injury (Chambers and Fallouh, 2010). The current 
study also investigated whether combined oCOm-21 infusion given prior to an ischaemic 
event and again upon reperfusion would provide additional benefits above pre-ischaemic 
infusion alone.   
 
4.2.1 Pre-ischaemic response to oCOm-21 
The positive inotropic response obtained from the infusion of oCOm-21, seen as an increase 
in the systolic pressure and an overall increase in LVDP, has been observed with CORMs 
developed by other research groups. Musameh and colleagues observed increases in 
ventricular systolic pressure by 25 – 30 mmHg in isolated perfused rat hearts following a 10-
minute infusion of CORM-3 (20 µg min -1) (Musameh et al., 2006). This transition metal 
based CORM is water soluble and rapidly releases CO in biological fluids (Motterlini et al., 
2002b; Clark et al., 2003; Guo et al., 2004). CORM-3 has a much faster half-life of ~1-
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minute compared to oCOm-21 (Guo et al., 2004). Interestingly, CORM-3 infusion (20 µg min 
-1) under a constant perfusion pressure did not produce an increase in CFR despite an 
inotropic response being recorded. In contrast, CORM-A1 a compound whose functional and 
CO release properties, but not its structure, closely resemble those of oCOm-21 (water 
soluble; T1/2 ~ 21-minutes at 37°C pH 7.4) did not produce an inotropic effect at any of the 
concentrations tested (3 – 30 µg/mL), however, the highest concentration of CORM-A1 
applied did increase CFR (Musameh et al., 2006). These results differ from the present study 
involving oCOm-21, where vasodilatory and positive inotropic responses were observed with 
the active but not inactive oCOm. All concentrations of oCOm-21 used (1, 3 and 10 µM) 
consistently increased CFRs upon infusion in normotrophic and hypertrophic hearts. Our 
research group has demonstrated the vasodilatory property of oCOm-21 and shown that the 
vasorelaxation is mediated by sGC/cGMP (Kueh et al., 2017). This is in line with the 
previous work by both Sammut and Wang who demonstrated CO induces vasodilation 
through cGMP (Wang et al., 1997; Sammut et al., 1998). Additionally, the current study 
showed that infusion of oCOm-21 (1 and 3 µM) in normotrophic hearts produced an increase 
in the maximum value of the differentiated LV rate pressure products (dP/dtmax and dP/dtmin). 
A study was conducted separately by another member of the CardioRenal Protection group 
where the impact of oCOm-21 in avascular cardiac tissue (human trabeculae) was 
investigated (Submitted data). The study showed oCOm-21 still produced a positive inotropic 
response in tissue seen as a concentration dependent (1 – 10 µM) contractile response. This 
data shows that the positive inotropic response obtained in the present study is independent to 
the increased CFR. This increased ventricular contractility and relaxation, in combination 
with the coronary vasodilation and consequent increase in CFR, is expected to improve 
perfusion and distribution of oCOm-21 in the heart. The pre-ischaemic inotropic responses to 
oCOm-21 observed in normotrophic hearts were also observed in the hypertrophic hearts 
albeit blunted (by 26% to 1 µM and by 16% to 3 µM oCOm-21) compared to the responses 
obtained in the normotrophic hearts. The increased total LV fibrosis (both interstitial and 
perivascular) present in the hypertrophic hearts may have been responsible for the blunted 
inotropic effect (Varnava et al., 2000). This attenuation may have occurred either as a 
consequence of an impaired distribution of the oCOm-21 throughout the myocardium or 
because of an impaired contractile response at a cellular level. This finding is not isolated to 
the present study; Ebrahim and colleagues observed that, while the vasodilatory effect of 
bradykinin treatment on coronary arteries was present in the normotensive hearts increasing 
CFR, the same effect was absent in in DOCA-salt hypertensive hearts with an increased LV 
 
 48 
mass, (Ebrahim et al., 2007). The absence of the bradykinin induced CFR increase in the 
hypertrophic hearts was associated with a decrease in the cardioprotective action of 
bradykinin during reperfusion following a coronary artery occlusion (Ebrahim et al., 2007).  
 
Sammut et al. have demonstrated that cellular CO elevation results in increased cGMP 
concentrations; this study consequently proposed this secondary messenger system may be 
the underlying mechanism for the LV contractility and relaxation observed with oCOm-21 
infusion (Sammut et al., 1998). Therefore, a pilot study (n = 3) was conducted infusing the 
irreversible sGC specific inhibitor, ODQ, into the hypertrophic hearts prior to oCOm-21 
infusion (Figure 3.14). This pilot study attempted to determine the optimal concentration of 
ODQ in order to inhibit coronary vascular sGC activity without adversely affecting LVDP. A 
concentration of 10 µM ODQ markedly reduced LVDP immediately on infusion in the 
absence of oCOm-21. The limited data obtained showed that while LVDP still fell in the 
presence of 5µM ODQ, oCOm-21 (3 µM) was still able to increase peak systolic and end 
diastolic pressures in these conditions. ODQ infusion did not attenuate either the oCOm-21 
mediated positive inotropic or CFR response (Figure 3.13). This finding will require further 
investigation, especially as Musameh et al. showed that infusion of ODQ (10 µM) prior to 
and throughout CORM-3 infusion blocked the inotropic response observed previously with 
CORM-3 (Musameh et al., 2006). The authors, however, did not indicate whether ODQ at 
this concentration adversely affected LV haemodynamics prior to CORM infusion.  
 
The pre-ischaemic response to oCOm-21 in the present study was examined further to show a 
positive correlation in the size of the inotropic response produced by oCOm-21 and the 
recovery of LVDP (Figure 3.15). This was observed with all concentrations of oCOm-21 (1, 3 
and 10 µM) when applied in the normotrophic hearts and with 3 µM in the hypertrophic 
hearts. This finding warrants further research needed to investigate the correlation and 
investigate the underlying signalling causing the positive inotropic response and how this 
relates to the triggering of protective signalling molecules. The ability to predict the 
haemodynamic recovery afforded by a myocardial conditioning agent prior to the ischaemic 
insult has significant clinical relevance as the dose of oCOm-21 could be adjusted to obtain a 
larger inotropic response to provide greater haemodynamic recovery following ischaemia in a 
cardiac surgical setting. Interestingly, the consistent positive inotropic response is unique to 
CO and is not present among other gaseous conditioning agents, for example H2S is a 




4.2.2 Post-ischaemic recovery in normotrophic hearts 
As highlighted in the introduction, myocardial ischaemia and subsequent reperfusion can 
impact upon the contractile function of the heart, cardiac output, coronary perfusion and cell 
death (Hausenloy and Yellon, 2016). The significant recovery of LVDP during the 
reperfusion period in the normotrophic hearts treated with oCOm-21 (1 and 3 µM) prior to 
ischaemia showed a significant reduction of post-ischaemic LV contractile dysfunction. 
Furthermore, 3 µM of oCOm-21 significantly improved LV contractility and relaxation 
recovery (compared to vehicle control and 1µM of oCOm-21) following 15-minutes of 
reperfusion, as determined by increases in both dP/dtmax and dP/dtmin. Infusion of oCOm-21 at 
10 µM did not produce significant recovery of LVDP in the reperfused normotrophic hearts. 
The absence of significance may be due to the large variation in the responses to 10 µM 
infusion and additional experimental numbers should be completed for this group before any 
solid conclusions on the effectiveness of the concentration is made. The improved LV 
haemodynamic function in the reperfused hearts was supported by the recovery of coronary 
flow with all concentrations of oCOm-21 (1, 3 and 10 µM) and return of the pre-ischaemic 
heart rate to baseline indices with oCOm-21 (1 and 3 µM).  
 
The significant recovery of LV haemodynamic function, afforded by oCOm-21, following 
ischaemia in the normotrophic hearts affirmed our hypothesis. The hypothesis was formed 
from experimental evidence in which exogenously applied CO has been shown to be a 
pharmacological cardioprotective agent (Clark et al., 2003; Fujimoto et al., 2004; Guo et al., 
2004; Clark et al., 2009; Stein et al., 2012; Adams et al., 2017). The ex vivo experimental 
study conducted in the normotrophic rat heart reconfirmed the prophylactic benefit and effect 
of oCOm-21 shown in a prior identical study by the CardioRenal Protection group in naïve 
male Sprague Dawley rat heart. In the previous study, 1 µM of oCOm-21 produced an 83.73 
% recovery of LVDP at 60 minutes (P < 0.05) while the present study obtained a recovery of 
56.37 % with the same concentration of oCOm-21 (Adams et al., 2017). The difference 
between the two studies may be explained by the age difference of the rats between the two 
studies. In the present study rats, were at 16 – 20 weeks of age at termination, while the 
Sprague Dawley rats in the previous study were at 10 weeks of age (270 – 300 g). Further 
investigations into the disparity are warranted as a species difference may be present and 
could hold significant implications for comparability between studies. This would require age 
matching the strains to determine if the difference is due to age or investigating other 
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parameters such as heart weight, LV fibrosis and left ventricular wall sizes to determine if the 
difference is otherwise due to structural alterations between strains.  
 
The cardioprotection afforded by the exogenous application of CO against I/R injury within 
the present study is further supported by work conducted previously by the CardioRenal 
Protection group in which inhaled CO delivered at 20 ppm in air for 24 hours prior to and for 
24 hours following left anterior descending (LAD) artery ligation surgery resulted in 
improved LVDP in normotrophic Lewis rat hearts (Parry, 2017). Clark and colleagues have 
also demonstrated CO delivered by CORM-3 as a preconditioning agent in a mouse heart 
reduced LV dysfunction (recovered systolic pressure, cardiac output and ejection fraction) 
and reduced infarct size in an in vivo LAD artery ligation surgical model of I/R injury (Clark 
et al., 2009).  
 
The present study has demonstrated the LVDP haemodynamic recovery in normotrophic 
hearts from preconditioning with a CO donor are comparable with results obtained using IPC 
by external research groups (Pantos et al., 1996; Barthel et al., 2004). The non-invasive 
application of oCOm-21 provides superiority over mechanical IPC which has been fraught 
with issues surrounding not only the practical application in a surgical setting but the 
increased thromboembolism risk as well especially in patients with co-morbidities. Barthel 
and colleagues showed following a 30 minutes ischaemic insult, IPC enhanced recovery of 
LVDP in isolated hearts at 60 minutes of reperfusion (48% recovery to baseline LVDP values 
against 13% in non-preconditioned control hearts) (Barthel et al., 2004). This was correlated 
by a decrease in the infarct size (Barthel et al., 2004). Similarly, Pantos and colleagues 
demonstrated an enhanced recovery of LVDP in isolated hearts at 45 minutes of reperfusion, 
following 20 minutes of ischaemia, when an IPC protocol was employed (76.5% recovery to 
baseline LVDP values against 49.3% in non-preconditioned control hearts) (Pantos et al., 
1996). Both of these studies discussed used young male Wistar rats. Recovery of LVDP with 
oCOm-21 in the normotrophic hearts in the present study was comparatively greater than the 
recovery reported with IPC by Barthel and colleagues when an identical duration of ischaemia 
and reperfusion was used (Barthel et al., 2004). The present study also produced a greater 
recovery of LVDP when compared to the study by Pantos and colleagues who used a shorter 
duration of ischaemia. This favourable comparison reinforces the clinical potential of oCOm-




4.2.3 Recovery in hypertrophic hearts 
The present study successfully showed that the pre-ischaemic infusion of oCOm-21 at the 
higher 3 and 10 µM concentrations was able to provide significant protection against I/R 
induced LV haemodynamic dysfunction in the hypertrophic hearts. In this study, hearts from 
the hypertensive rats were separated according to HW and severity of hypertrophy to form the 
two groups; moderately hypertrophic hearts and severely hypertrophic hearts. This 
stratification was conducted as previous work has shown a relationship between the severity 
of LVH and the susceptibility of myocardium to I/R injury, which has been shown to affect 
postoperative outcomes in patients undergoing cardiac surgical interventions (Beyersdorf et 
al., 1980; Itoh et al., 2004; Meijs et al., 2010). Furthermore, it has previously been 
demonstrated that the cardioprotective effects of conditioning therapies can be negated in 
severely hypertrophied hearts (Ghosh et al., 2001; Itoh et al., 2004; Ma et al., 2018). The 
current study demonstrated that oCOm-21 affords moderately hypertrophic hearts significant 
protection against I/R induced LV dysfunction with 3 µM of oCOm-21 shown to be the 
optimal dose for cardioprotection. The pre-ischaemic infusion of 3 µM oCOm-21 
significantly and rapidly improved recovery of LVDP, CFR and heart rate during the 
reperfusion period to pre-ischaemic values, above the values obtained in the vehicle control 
group.   
 
A reduced ischaemic recovery response to the cardioprotective effects of oCOm-21 was 
observed in the moderately and severely hypertrophic hearts in comparison to the 
normotrophic hearts. Furthermore, it was demonstrated that the reduced oCOm-21 
cardioprotection was associated with the severity of hypertrophy. For example, the complete 
recovery of LVDP afforded by 3 µM of oCom-21 in the normotrophic hearts was reduced by 
28.8% in the moderately hypertrophic hearts to 72.80 ± 24.55 % and reduced by 67.85% in 
the severely hypertrophic hearts to 32.87 ± 13.0 %. The reduced LVDP recovery in these 
moderately and severely hypertrophic hearts was accompanied by reductions in the recovery 
of CFR during reperfusion, consistent with increased susceptibility to the ischaemic insult and 
the subsequent reperfusion injury. 
 
No significant difference in the LVDP recovery was observed between normotrophic and 
hypertrophic vehicle control groups. This finding suggests a reduction in the cardioprotective 
ability of oCOm-21 with increasing disease burden rather than an increased susceptibility to 
I/R injury as first hypothesised. The reduction in cardioprotection observed may therefore be 
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due to an inability to distribute oCOm-21 throughout the myocardial tissue as a consequence 
of the known structural alterations observed in cardiac hypertrophy affecting tissue perfusion 
(narrowing of microvasculature lumen, microvascular remodelling, cardiomyocyte 
hypertophy and replacement fibrosis) (Varnava et al., 2000). To investigate this theory a 
fluorescently tagged compound could be synthesised and perfused through the myocardium to 
assess distribution or a dye with a similar molecular weight to oCOm-21. Furthermore, 
increasing the duration of pre-ischaemic infusion could be examined to overcome the reduced 
effect of preconditioning in these hypertrophied hearts. The increased duration of oCOm-21 
infusion could allow for greater diffusion and distribution of oCOm-21 in the compromised 
tissue of disease burdened hearts.  
 
The reduced ability to precondition hearts burdened with LVH has also been observed by Ma 
and colleagues when they investigated the effect of the pharmacological cardioprotective 
agent, rapamycin, in a model of myocardial I/R injury in isolated mice hearts burdened with 
LVH (Ma et al., 2018). Ma et al. observed cardioprotection in the non-diseased control hearts, 
however, in hearts burdened with LVH, rapamycin cardioprotection was attenuated shown by 
increased infarct size, increased cardiomyocyte apoptosis and worsening of cardiac function 
(Ma et al., 2018). In contrast, Pantos and colleagues did not observe an attenuated response to 
manual IPC in isolated hearts burdened with LVH and this has also been shown in subsequent 
studies by other research groups (Speechly-Dick et al., 1994; Pantos et al., 1996; Ebrahim et 
al., 2007; Fantinelli and Mosca, 2007). A possible explanation for the preservation of IPC 
cardioprotection in these studies may have been attributable to the degree of cardiac 
hypertrophic burden. In the 1996 study by Pantos et al. the HW/BW ratio for the 
normotrophic control hearts from Wistar rats was 0.281 g of HW /100g of BW and the ratio 
for the hypertrophic hearts was 0.366 g/100g (Pantos et al., 1996). These values are 
considerably less than those obtained in our Cyp1a1-Ren2 hypertrophic hearts (0.521 – 0.676 
g/100g). Speechly-Dick and colleagues observed marginally improved rate pressure product 
values with IPC obtained in DOCA-salt induced hypertensive Sprague Dawley rats (250 – 
350 g) where a 45 % increase in HW was obtained against the non-hypertensive control, 
while Fantinelli and Mosca reported no change in IPC cardioprotection with an increased HW 
of 21.5 % between the hypertensive SHR and non-hypertensive control (Speechly-Dick et al., 
1994; Fantinelli and Mosca, 2007). The severity of cardiac hypertrophy appears to be a 
consistent factor for the retained cardioprotection of IPC. The 45 % increase of HW in the 
Speechly-Dick et al. study correlates to the moderately hypertrophic group in the current 
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study where a 40 % increase in HW was obtained, however, the present study still obtained a 
significant recovery of LV haemodynamic measurements with oCOm-21 pre-ischaemic 
treatment. Of interest, in the Speechly-Dick et al. study, a decrease in cardioprotection with 
IPC was observed in the hypertrophic hearts against non-hypertrophic hearts (Speechly-Dick 
et al., 1994) which falls in line with the findings observed in the present study with oCOm-21 
in the hypertrophic hearts.   
 
4.2.4 Combined pre-ischaemic and post-ischaemic infusion of oCOm-21 
The combined infusion of oCOm-21 (1 and 3 µM) in normotrophic hearts before the 
ischaemic event and upon reperfusion did not provide the hypothesised additional benefit 
above pre-ischaemic infusion alone. Instead the pre-ischaemic and post-ischaemic dosing 
protocol of oCOm-21 was detrimental to LVDP recovery. Initially, within the first minute of 
reperfusion, LVDPs in hearts pre-treated with oCOm-21 (1 and 3 µM) were higher than in the 
vehicle control hearts. By 5 minutes into the reperfusion period, the LVDP in these oCOm-21 
treated hearts had dropped below the initial reperfusion LVDP. These results imply that the 
infusion of oCOm-21 immediately upon reperfusion may inflict damage above and beyond 
that of I/R injury alone. It has been established that the restoration of O2 to the 
cardiomyocytes with reperfusion triggers a large burst of ROS, intracellular Ca2+ overload 
and mitochondrial damage (Zweier et al., 1987; Grill et al., 1992). Therefore, this study 
suggests that the apparent detrimental effect of oCOm-21 infusion at 5 minutes of reperfusion 
may be due to the established conditioning mechanism of CO in which the mitochondrial 
ETC activity is reduced, consequently, enhancing a small burst of mitochondrial ROS and 
decreasing ATP production (Sandouka et al., 2005; Lo Iacono et al., 2011; Kaczara et al., 
2015). These events occurring during the early reperfusion phase could add to the 
mitochondrial injury triggering a permanent opening of the mPTP leading to cell death 
(Lindsay et al., 2015; Seidlmayer et al., 2015). This theory could be tested using a technique 
such as electron paramagnetic resonance spectroscopy, as described by Griendling and 
colleagues (Griendling et al., 2016) for ROS determination in IR injured myocardium win the 
presence and absence of the CO donor.  
 
To date experimental protocols for assessing the prophylactic benefit of pharmacological 
post-conditioning agents have been primarily conducted in in vivo surgical models where the 
agent has been given as a bolus 5 – 10 minutes prior to reperfusion (Guo et al., 2004; Piot et 
al., 2008; Karwi et al., 2016). The investigation of CORM-3 as a pharmacological 
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postconditioning agent by Guo and colleagues was conducted in an acute myocardial 
infarction surgical model, in this protocol infusion of CORM-3 (total dose, 3.54 mg/kg) began 
5 minutes prior to reperfusion and infusion continued until 55 minutes into reperfusion (Guo 
et al., 2004). In the 2004 study, CORM-3 was shown to be cardioprotective as a 
postconditioning agent by demonstrating a reduction in myocardial infarct size (Guo et al., 
2004). The authors further concluded that CORM-3 was as efficacious as IPC and IPostC 
protocols due to a similar reduction in the size of myocardial infarct among the groups (Guo 
et al., 2004). The study by Guo et al. suggests that CO itself is not the reason for the 
decreased LVDP seen in our present study with oCOm-21 post-ischaemic infusion but rather 
that the parent oCOm compound needs to be distributed through the myocardium at an 
optimal concentration at the onset of reperfusion  (De Hert et al., 2004; Piot et al., 2008).  
 
4.3 Myocardial Cell Death 
4.3.1 Necrotic cell death 
The presence of the cytosolic enzyme LDH in coronary effluent is a marker of plasma 
membrane integrity loss associated with necrosis and is an accepted biochemical marker for 
myocardial injury (Apple et al., 2001; Bodor, 2016). Earlier preliminary studies by our group 
showed that infusion of 1 µM oCOm-21 did not increase LDH release in isolated normoxic 
Sprague-Dawley rat hearts confirming that oCOm-21 was not cardiotoxic (unpublished data). 
In line with the initial hypothesis, no significant increases were observed in LDH release upon 
reperfusion following oCOm-21 infusion (1, 3 and 10 µM) prior to ischaemia in normotrophic 
hearts. The protection against necrosis in the normotrophic hearts, with oCOm-21, correlates 
with the significant recovery of LV haemodynamic parameters. Several research groups have 
demonstrated that LV haemodynamic recovery following ischaemia is associated with 
improved coronary perfusion, reduced mitochondrial damage and reduced markers of necrosis 
(Clark et al., 2009; Farine et al., 2016; Lindsey et al., 2018). The absence of a significant 
elevation in LDH activity upon the first minute of reperfusion, in vehicle control treated 
hearts, was unexpected given the large body of evidence demonstrating I/R injury leads to 
significant increases in necrotic cell death markers and infarct sizes (Jennings et al., 1960; 
Yamahara et al., 1993; Hausenloy and Yellon, 2016).  
 
Both the higher concentrations of oCOm-21, 3 µM and 10 µM, were able to protect the 
moderately and severely hypertrophic hearts against necrosis upon reperfusion, as seen by the 
non-significant LDH levels when directly compared to the baseline values. Our results from 
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this study correspond with work published by Clark and colleagues showing that infarct size 
and necrotic markers deceased in CORM-3 treated hearts in association with a significant 
improvement of LVDP recovery in isolated Lewis rat hearts (Clark et al., 2003). Although the 
study by Clark et al. was conducted using a post-conditioning protocol, the ability to reduce 
necrosis with CO remains relevant (Clark et al., 2003). The same group, also showed that 
CORM-3 administered prior to a LAD coronary artery occlusion led to reductions in 
myocardial infarct size and improved LV haemodynamic recovery (Clark et al., 2009). 
  
Given the reduced LV haemodynamic recovery with 1 µM infusion of oCOm-21, in both the 
moderately and severely hypertrophic hearts, it is unsurprising that 1 µM oCOm-21 was 
unable to prevent a significant increase in LDH activity within the first minute of reperfusion. 
Therefore the hypothesis was formed that the cellular and structural alterations associated 
with LVH impaired the distribution of oCOm-21 throughout the myocardial tissue, resulting 
in the lower concentration of oCOm-21 (1 µM) being unable to adequately protect against I/R 
induced necrosis. This hypothesis is supported when assessing the LDH activity during the 
initial reperfusion period between the moderately and severely hypertrophic hearts, with the 
severely hypertrophic hearts having a greater LDH activity. Previous clinical studies suggest 
that there is a persistent elevation of cardiac enzymes including LDH in patients with 
hypertrophic cardiomyopathy indicative of an ongoing myocardial injury (Hamada et al., 
2015). This finding of increased LDH leakage in the hypertrophied hearts also suggests that 
that there may be less myocardium to salvage after I/R injury in these pre-morbid hearts. 
 
Currently this study is unable to determine why the vehicle treated hearts did not produce 
significant elevations in the level of LDH. In future studies another collection of the coronary 
effluent for LDH analysis should occur at 5 minutes of reperfusion. It is known that a large 
proportion of the reperfusion injury occurs in the first few minutes following the 
reinstatement of perfusion, therefore, the degree of cell death by necrosis may be understated 
in the vehicle control treated hearts and may account for the absence of a significant elevation 
from baseline values (Piper et al., 2004; Prasad et al., 2009).  
 
4.3.2 Apoptotic cell death 
The anti-apoptotic potential of CO has been well established (Zhang et al., 2005; Chin et al., 
2007; Kim et al., 2007; Kondo-Nakamura et al., 2010). While this study did not observe any 
significant reductions in apoptotic cell death in the LV anterior wall of oCOm-21 treated 
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normotrophic hearts, a trend showing a reduction was observed. In hypertrophic hearts by 
comparison significant decreases in apoptotic cell death in LV anterior wall in the hearts 
treated with 1 and 3 µM of oCOm-21 were observed. As discussed in the above section, 
reductions in cell death improve LV haemodynamic recovery following ischaemia. The 
CardioRenal Protection lab has previously shown that oCOm-21 decreases PKCε from the 
cytosolic component of the cardiomyocytes suggesting oCOm-21 increases the translocation 
of PKCε to the mitochondrial compartment (Adams et al., 2017). The activation and 
translocation of this pro-survival protein kinase, PKCε, into the mitochondria protects against 
I/R cell death by inhibiting the opening of the mPTP (Liu et al., 1995; Costa and Garlid, 
2008; Budas et al., 2010).  
 
Images for the ApopTag analysis in this study were taken from random sections in the left 
ventricular anterior wall. This section of the heart was chosen as it is primarily supplied by 
the left anterior descending (LAD) coronary artery, a key coronary artery used in in vivo 
experimental research for assessing I/R injury and various cardioprotection therapies (Murry 
et al., 1986; Schott et al., 1990; Cohen et al., 1991; Clark et al., 2009; Lindsey et al., 2018). 
The analysis of apoptosis solely from the left ventricular anterior wall poses a potential 
limitation as apoptosis throughout the left ventricle may not be fully represented. Before 
publication at least ten further images from random sections of the left ventricular will need to 
be taken and quantified for each heart.  
 
4.4 Conclusion and Study Significance 
This study developed a clinically relevant model of HHD in the transgenic Cyp1a1-Ren2 rat. 
The study successfully demonstrated that ingestion of a low dose of 0.167 % w/w I3C over a 
period of 8 – 12 weeks leads to sustained HTN as a precursor to increased HW and 
significantly elevated LV fibrosis. This LVH animal model will provide significant benefit for 
future testing of cardioprotective drugs in a heart burdened with comorbidities.  
 
Conditioning agents to date have been largely tested in hearts unburdened with comorbidities 
which is not representative of the population of patients undergoing cardiac surgical 
interventions (Hausenloy and Yellon, 2016). To the best of the researcher’s knowledge this is 
the first study in which exogenously applied CO has been investigated for cardioprotection 
against myocardial I/R injury in a heart burdened with LVH. This study successfully 
demonstrated that infusion of the novel CO donor, oCOm-21 prior to an ischaemic event 
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significantly protected normotrophic and moderately hypertrophic hearts against I/R induced 
LV haemodynamic dysfunction during reperfusion (LVDP, dP/dtmax dP/dtmin, heart rate and 
CFR recovery) and reduced cell death in an isolated perfused heart. The ability to protect a 
heart burdened with LVH provides significant benefit in acute cardiac surgical interventions 
utilising CPB where the heart undergoes a period of ischaemia triggering I/R injury. Rapid 
improvement of LV contractile function as observed in this study with oCOm-21 is 
imperative in the surgical setting to prevent the incidence and severity of complications, such 
as low-output cardiac failure, myocardial infarction and stroke. Furthermore, oCOm-21 pre-
ischaemic infusion afforded recovery of CFR during reperfusion which has clinically 
significant as the reinstallation of myocardial perfusion at the completion of a surgical 
intervention utilising CPB can result in a phenomenon termed no-reflow where in some 
patients, despite adequate input, myocardial tissue failures to adequately perfuse (Kloner et 
al., 1974; Boyle et al., 1996; Reffelmann and Kloner, 2002; Zhao et al., 2007). No-reflow can 
lead to a number of complications and can ultimately result in myocardial infarction and death 
(Ito et al., 1992; Alfayoumi et al., 2005).  
 
4.5 Methodological Evaluation  
4.5.1 Animal model 
• Normotrophic and hypertrophic heart numbers 
o The normotrophic section of the study originally included n = 5 normotrophic 
hearts per treatment group for the assessment of the pre-ischaemic infusion of 
oCOm-21. 6 hearts had to be excluded from this study due to rapid 
deterioration during the equilibration stage of the Langendorff protocol (prior 
to any manipulation). This was identified as an issue with unopened heparin 
ampoules stored at 4 °C for greater than 2 months. The hypertrophic section of 
the study originally included n = 5 moderately and n = 5 severely hypertrophic 
hearts per treatment group for the assessment of the pre-ischaemic infusion of 
oCOm-21. In the study predicting the severity of LVH prior to termination was 
not possible, therefore the 1 and 10 µM oCOm-21 concentrations in 
moderately and severely hypertrophic groups were uneven. 8 hearts were 
excluded in this study for failure to meet the inclusion criteria of ≥ 70 mmHg 
LVDP. Furthermore, 4 hearts were excluded from the hypertrophic group due 
to systolic pressure instability resulting from volume overloading of the LV 
balloon. This was the consequence of initial inexperience of using severely 
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hypertrophic hearts where only very small volumes were required to be loaded 
in the balloon to achieve maximum LVDP. To rectify the issue a smaller 
balloon was used and volume was loaded in very small increments following 
balloon insertion into in the LV. Reduced n numbers impacts upon the power 
to detect a significant difference between groups, therefore the effect of 
oCOm-21 on LV haemodynamic recovery and reduction of cell death may be 
underestimated in this study (Button et al., 2013). Additional n numbers will 
be required for some of the treatment groups prior to publication.  
 
• Development of HTN in the human population tends to occur during middle age, 
therefore a possible limitation of this study is the use of young rats (16 – 20 weeks 
old) (Kearney et al., 2005).  
 
4.5.2 Molecular study  
• In this study the ApopTag kit was used. This kit involves the in situ labelling of DNA 
strand breaks by the TUNEL method. Identification of apoptosis by DNA 
fragmentation is a very common practise in a large number of studies (Dumont et al., 
2000; Palojoki et al., 2001; Kabakov and Gabai, 2018). This method does however 
have the limitation of identifying only end-stage apoptosis (Dumont et al., 2000). 
Therefore, looking at an upstream mediator of apoptotic cell death, such as caspase 3, 
through a caspase activity assay will provide a more accurate reflection of the total 
apoptotic cell death. Assessing an upstream apoptotic specific mediator will also 
exclude the concerns which have arisen in the literature suggesting the assessment of 
apoptosis by DNA fragmentation can lead to false-positive staining of necrotic cells 
(Hughes and Gobe, 2007). The other limitation of this section of the study arises from 
the inability to distinguish between cardiomyocyte apoptosis and apoptosis in other 
cell types such as inflammatory cells. Double-labelling of cardiomyocytes was not 








4.6 Future Directions  
4.6.1 Molecular studies 
• Investigate the expression of cytosolic and mitochondrial PKCε in the hypertrophic 
hearts from this study following I/R injury and the ability of oCOm-21 to increase 
translocation of PKCε to the mitochondria by the western blot method.      
 
• CD68 immunohistochemical staining to determine macrophage infiltration in isolated 
and in vivo in hearts burdened with pressure induced LVH.  
 
• Quantification of the perivascular and interstitial components of the total LV fibrosis 
in the hypertrophic hearts in the present study. This will be conducted prior to 
publication.  
 
• Assess perfusion and distribution throughout the myocardial tissue in hypertrophic 
hearts with a fluorescently tagged oCOm or a cardiac dye. 
 
• Further investigate the oCOm-21 mediated inotropic response in an isolated heart by 
using a range of signalling molecule and ion channel inhibitors including a NO 
inhibitor (L-Name), a L-type Ca2+ inhibitor (nifedipine), a PKC inhibitor 
(chelerythrine), a NHE inhibitor (amiloride) and completion of the sGC inhibitor 
(ODQ).  
 
4.6.2 Animal studies 
• Establish the in vivo pharmacokinetic characteristics of oCOm-21.  
 
• Assess the prophylactic benefit of oCOm-21 in an in vivo MI surgical model for 
assessment of cardioprotection following LAD coronary artery ligation.  
 
• Assess the prophylactic benefit of oCOm-21 in isolated hypertrophic hearts of middle 
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